WO2003068757A9 - Novel pyridin- and pyrimidin-derivatives - Google Patents

Novel pyridin- and pyrimidin-derivatives Download PDF

Info

Publication number
WO2003068757A9
WO2003068757A9 PCT/EP2003/001107 EP0301107W WO03068757A9 WO 2003068757 A9 WO2003068757 A9 WO 2003068757A9 EP 0301107 W EP0301107 W EP 0301107W WO 03068757 A9 WO03068757 A9 WO 03068757A9
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
aminomethyl
ylamine
pyrimidin
dichloro
Prior art date
Application number
PCT/EP2003/001107
Other languages
French (fr)
Other versions
WO2003068757A1 (en
Inventor
Markus Boehringer
Bernd Michael Loeffler
Jens-Uwe Peters
Matthias Steger
Peter Weiss
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to EP03704536A priority Critical patent/EP1476435B1/en
Priority to JP2003567888A priority patent/JP4359146B2/en
Priority to BR0307665-2A priority patent/BR0307665A/en
Priority to AT03704536T priority patent/ATE472536T1/en
Priority to AU2003206833A priority patent/AU2003206833B2/en
Priority to CA002474578A priority patent/CA2474578C/en
Priority to MXPA04007744A priority patent/MXPA04007744A/en
Priority to DE60333166T priority patent/DE60333166D1/en
Priority to KR1020047012449A priority patent/KR100608414B1/en
Publication of WO2003068757A1 publication Critical patent/WO2003068757A1/en
Publication of WO2003068757A9 publication Critical patent/WO2003068757A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention is concerned with pyridin- and pyrimidin-derivatives, their manufacture and their use as medicaments.
  • the invention relates to compounds ofthe formula (I)
  • X is N or C-R 5 ;
  • R 1 and R 2 are independently hydrogen or lower alkyl
  • R 3 is heterocyclyl; heterocyclyl mono-, di-, or tri-substituted, independently, by lower alkyl, perfluoro-lower alkyl, amino, lower alkoxy or halogen; aryl; or aryl mono-, di-, or tri-substituted, independently, by halogen, lower alkyl, amino, lower alkoxy or perfluoro-lower alkyl;
  • R 4 is lower alkyl; lower alkoxy; lower alkylthio; heterocyclyl; heterocyclyl mono-, di-, or tri-substituted, independently, by lower alkyl, lower alkoxy, perfluoro-lower alkyl, amino or halogen; aryl; aryl mono-, di-, or tri-substituted, independently, by lower alkyl, lower alkoxy, halogen, amino, or perfluoro-lower alkyl; aryloxy lower alkyl or cycloalkyl;
  • R 5 is hydrogen or lower alkyl; and pharmaceutically acceptable salts thereof.
  • DPP-IN dipeptidyl peptidase IV
  • GLP-1 glucagon like peptide 1
  • Inhibiting DPP-IN would potentiate the effect of endogenous GLP-1, and lead to higher plasma insulin concentrations.
  • higher plasma insulin concentration would moderate the dangerous hyperglycaemia and accordingly reduce the risk of tissue damage.
  • DPP-IN inhibitors have been suggested as drug candidates for the treatment of impaired glucose tolerance and type 2 diabetes mellitus (e.g. Vilhauer, WO98/19998).
  • Other related state of the art can be found in WO 99/38501, DE 19616486, DE 19834591, WO 01/40180, WO 01/55105, US 6110949, WO 00/34241 and US6011155.
  • the compounds ofthe present invention are useful for the treatment and/or prophylaxis of diabetes, particularly non-insulin dependent diabetes mellitus, and/or impaired glucose tolerance, as well as other conditions wherein the amplification of action of a peptide normally inactivated by DPP-IV gives a therapeutic benefit.
  • the compounds ofthe present invention can also be used in the treatment and/or prophylaxis of obesity Bowl disease, Colitis Ulcerosa, Morbus Crohn, and/or metabolic syndrome.
  • the compounds ofthe present invention can be used as diuretic agents and for the treatment and/or prophylaxis of hypertension.
  • the compounds ofthe present invention exhibit improved therapeutic and pharmacological properties compared to other DPP IV inhibitors known in the art, such as e.g. in context with pharmacokinetics and bioavailability.
  • lower is used to mean a group consisting of one to six, preferably of one to four carbon atom(s).
  • halogen refers to fluorine, chlorine, bromine and iodine, with fluorine, bromine and chlorine being preferred. Most preferred halogen is chlorine.
  • alkyl refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to twenty carbon atoms, preferably one to sixteen carbon atoms, more preferably one to ten carbon atoms.
  • lower alkyl alone or in combination with other groups, refers to a branched or straight-chain monovalent alkyl radical of one to six carbon atoms, preferably one to four carbon atoms.
  • This term is further exemplified by radicals such as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, isobutyl, t-butyl, n-pentyl, 3-methylbutyl, n- hexyl, 2-ethylbutyl and the like.
  • radicals such as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, isobutyl, t-butyl, n-pentyl, 3-methylbutyl, n- hexyl, 2-ethylbutyl and the like.
  • Preferable lower alkyl residues are methyl and ethyl, with methyl being especially preferred.
  • perfluoro-lower alkyl refers to a lower alkyl group wherein all ofthe hydrogens ofthe lower alkyl group are substituted or replaced by fluoro.
  • preferred perfluoro-lower alkyl groups are trifiuoromethyl, pentafluoroethyl and heptafluoropropyl, with trifiuoromethyl being especially preferred.
  • alkoxy refers to the group R'-O-, wherein R' is alkyl.
  • lower- alkoxy refers to the group R'-O-, wherein R' is lower-alkyl.
  • Examples of lower alkoxy groups are e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy and hexyloxy, with methoxy being especially preferred.
  • lower alkylthio refers to the group R'-S-, wherein R' is lower-alkyl as defined above.
  • cycloalkyl refers to a monovalent carbocyclic radical of three to six, preferably three to five carbon atoms. This term is further exemplified by radicals such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, with cyclopropyl being preferred.
  • heterocyclyl refers to a saturated, unsaturated or aromatic monovalent 5- to 7-membered monocyclic, 9-membered bicyclic or 13-membered tricyclic radical having at least one heteroatom selected from nitrogen, sulfur and oxygen, or a combination thereof.
  • heterocyclyl residues are pyridyl, pyrimidinyl, furyl, thienyl, indolyl, benzo[l,3]dioxolyl, benzofuranyl, benzothiophenyl, dibenzofuranyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, oxatriazolyl, thiatriazolyl, pyridazyl, pyrimidinyl, pyrazinyl, pyrrolidinyl, azepanyl, and morpholino.
  • Said heterocyclyl residues may be mono-, di- or tri-substituted, independently, by halogen, amino, perfluoro-lower alkyl, lower alkyl or lower alkoxy, preferably by lower alkyl or lower alkoxy.
  • aryl refers to an aromatic monovalent mono- or polycarbocyclic radical, such as phenyl and naphthyl, preferably phenyl, which may optionally be mono-, di- or tri-substituted, independently, by lower alkyl, lower alkoxy, halogen, amino or perfluoro- lower alkyl, preferably by lower alkyl, lower alkoxy and halogen.
  • aryloxy lower alkyl refers to an aryl residue as defined above attached to a lower alkylene group via an oxy radical, i.e. aryl-O-R, wherein R is lower alkylene.
  • pharmaceutically acceptable salts embraces salts ofthe compounds of formula (I) with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid, phosphoric acid, citric acid, formic acid, maleic acid, acetic acid, fumaric acid, succinic acid, tartaric acid, methanesulphonic acid, salicylic acid, p- toluenesulphonic acid and the like, which are non toxic to living organisms.
  • Preferred salts with acids are formates, maleates, citrates, hydrochlorides, hydrobromides and methanesulfonic acid salts, with hydrochlorides being especially preferred.
  • R 1 is lower alkyl, with methyl and isopropyl being preferred. In a preferable embodiment, R 1 is hydrogen.
  • R 2 is lower alkyl, with methyl being preferred. In a preferable embodiment, R 2 is hydrogen.
  • X is N. In another embodiment, X is C-R 5 . Preferable X is N.
  • R 3 is heterocyclyl, such as pyridyl, pyrimidinyl, furyl, thienyl, indolyl, benzo[l,3]dioxolyl, benzofuranyl, benzothiophenyl, dibenzofuranyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, oxatriazolyl, thiatriazolyl, pyridazyl, pyrazinyl, pyrrolidinyl, azepanyl and morpholino, which hterocyclyl residues may optionally mono-, di- or tri-substituted, independently, by lower alkyl, lower alkoxy, perfluoro-lower alkyl, amino or halogen,
  • Preferred heterocyclyl residues R 3 are unsubstituted thienyl and unsubstituted benzo[l,3]dioxolyl.
  • R 3 is aryl, preferably phenyl, optionally ortho-, meta- and/or para-, preferably ortho- and para- substituted, independently, by lower alkyl, lower alkoxy, halogen, amino or perfluoro-lower alkyl, preferably by halogen, lower alkyl, perfluoro- lower alkyl or lower alkoxy.
  • Most preferable residue R 3 is 2,4-dichloro-phenyl.
  • R 4 is aryl such as phenyl or naphthyl, with phenyl being preferred.
  • Phenyl residues R 4 may optionally be ortho-, meta- and/or p ⁇ r -substituted, independently, by halogen, amino, lower alkyl, perfluoro-lower alkyl or lower alkoxy, preferably by halogen, such as fluoro, by lower alkyl, such as methyl or lower alkoxy, such as methoxy.
  • Naphthyl residues R 4 are preferably unsubstituted or mono-substituted by lower alkoxy, such as methoxy.
  • R 4 is lower alkoxy, preferably methoxy.
  • R 4 is lower alkyl. Preferable lower alkyl residues R 4 are methyl and isopropyl. In another embodiment R 4 is cycloalkyl, with cyclopropyl being preferred. In another embodiment R 4 is lower alkylthio, preferably methylthio. In another embodiment R 4 is heterocyclyl.
  • Preferable heterocyclyl residues R 4 are pyridyl, pyrimidinyl, furyl, thienyl, indolyl, benzo[l,3]dioxolyl, benzofuranyl, benzothiophenyl, dibenzofuranyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, oxatriazolyl, thiatriazolyl, pyridazyl, pyrimidinyl, pyrazinyl, pyrrolidinyl, azepanyl, and morpholino.
  • heterocyclyl residues may optionally be mono-, di- or tri-substituted, preferably mono- or di- substituted, independently, by halogen, amino, perfluoro-lower alkyl, lower alkyl or lower alkoxy, preferably by lower alkyl or lower alkoxy.
  • R 4 is aryloxy lower alkyl.
  • Preferable aryloxy lower alkyl is phenoxy lower alkyl, wherein the phenyl moiety is substituted by halogen.
  • Most preferable aryloxy lower alkyl is 4-fluorophenoxymefhyl.
  • R 5 is lower alkyl, with methyl being preferred. In another embodiment, R 5 is hydrogen.
  • Preferred compounds in accordance with the present invention are those compounds of formula I, wherein X is N, R 1 and R 2 are hydrogen, R 3 is an aryl residue as defined above, preferably a phenyl residue which is ortho- and p ⁇ r -substituted, independently, by lower alkyl, lower alkoxy, halogen, amino or perfluoro-lower alkyl, most preferably 2,4-dichloro-phenyl, and R 4 is alkoxy, preferably methoxy, alkylthio, preferably methylthio, aryl, preferably a phenyl reside which may optionally be ortho-, meta- and/or p ⁇ ra-substituted, independently, as defined above, preferanly by by halogen, such as fluoro, by lower alkyl, such as methyl or lower alkoxy, such as methoxy, or a heterocyclyl residue as defined above, preferably pyrrolidinyl or azepanyl.
  • Preferred compounds of general formula (I) are those selected from the group consisting of:
  • the compounds of general formula (I) in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.
  • the present invention also relates to a process for the manufacture of compounds of formula I.
  • This process comprises the reduction of nitriles of formulae IV, IVa, IX and IXa to amines of formulae la and lc, respectively.
  • This reduction can be performed according to methods known in the art.
  • the reduction can be carried out using a metal hydride such as lithium aluminum hydride in an inert solvent.
  • Nitriles of formulae IV and IVa are known in the art or can be prepared from arylidene malononitriles of formula V and amidines VII by processes known in the art.
  • the reaction can be performed in the presence of a base such as potassium carbonate in an inert solvent such as methanol.
  • Nitriles of formula IX and IXa are known in the art or can be prepared by processes known in the art.
  • One such process is the reaction of arylidene malononitriles of formula V and ketones of formula X.
  • the reaction can be performed by heating with ammonium acetate in an inert solvent such as methanol.
  • Arylidene malononitriles of formula V are known in the art or can be prepared by processes known in the art, for instance by reaction of aromatic aldehydes VI with malononitrile in the presence of a base such as piperidine.
  • Amidines of formula VII are known in the art or can be prepared by processes known in the art.
  • amidines of formula VII can be prepared from nitriles VIII by a process known in the art as the Pinner reaction.
  • the invention further relates to compounds of formula (I) as defined above, when manufactured according to a process as defined above.
  • the compounds of formula (I) ofthe present invention can be used as medicaments for the treatment and/or prophylaxis of diseases which are associated with DPP IV such as diabetes, particularly non-insulin dependent diabetes mellitus, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn, obesity, and/or metabolic syndrome , preferably non-insulin dependent diabetes mellitus and/or impaired glucose tolerance.
  • diseases which are associated with DPP IV such as diabetes, particularly non-insulin dependent diabetes mellitus, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn, obesity, and/or metabolic syndrome , preferably non-insulin dependent diabetes mellitus and/or impaired glucose tolerance.
  • the compounds ofthe present invention can be used as diuretic agents or for the treatment and/or prophylaxis of hypertension.
  • the invention therefore also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable carrier and/or adjuvant.
  • the invention relates to compounds as defined above for use as therapeutic active substances, particularly as therapeutic active substances for the treatment and/or prophylaxis of diseases which are associated with DPP IV such as diabetes, particularly non-insulin dependent diabetes mellitus, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn, obesity, and/or metabolic syndrome, preferably for use as therapeutic active substances for the treatment and/or prophylaxis of non-insulin dependent diabetes mellitus and/or impaired glucose tolerance.
  • the invention relates to compounds as defined above for use as diuretic agents or for use as therapeutic active substances for the treatment and/or prophylaxis of hypertension.
  • the invention relates to a method for the treatment and/or prophylaxis of diseases which are associated with DPP IV such as diabetes, particularly non-insulin dependent diabetes mellitus, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn, obesity, and/or metabolic syndrome, preferably for the treatment and/or prophylaxis of non-insulin dependent diabetes mellitus and/or impaired glucose tolerance, which method comprises administering a compound as defined above to a human being or animal.
  • the invention relates to a method for the treatment and/or prophylaxis as defined above, wherein the disease is hypertension or wherein a diuretic agent has a beneficial effect.
  • the invention further relates to the use of compounds as defined above for the treatment and/or prophylaxis of diseases which are associated with DPP IV such as diabetes, particularly non-insulin dependent diabetes mellitus, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn, obesity, and/or metabolic syndrome, preferably for the treatment and/or prophylaxis of non-insulin dependent diabetes mellitus and/or impaired glucose tolerance.
  • diseases which are associated with DPP IV
  • diseases which are associated with DPP IV such as diabetes, particularly non-insulin dependent diabetes mellitus, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn, obesity, and/or metabolic syndrome, preferably for the treatment and/or prophylaxis of non-insulin dependent diabetes mellitus and/or impaired glucose tolerance.
  • the invention relates to the use as defined above, wherein the disease is hypertension or to the use as diuretic agent.
  • the invention relates to the use of compounds as defined above for the preparation of medicaments for the treatment and/or prophylaxis of diseases which are associated with DPP IV such as diabetes, particularly non-insulin dependent diabetes mellitus, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn, obesity, and/ or metabolic syndrome, preferably for the treatment and/or prophylaxis of non-insulin dependent diabetes mellitus and/or impaired glucose tolerance.
  • diseases which are associated with DPP IV
  • Such medicaments comprise a compound as defined above.
  • the invention relates to the use as defined above, wherein the disease is hypertension or the use for the preparation of diuretic agents.
  • the following diseases relate to a preferred embodiment: diabetes, particularly non-insulin dependent diabetes mellitus, impaired glucose tolerance, obesity, and/or metabolic syndrome, preferably non-insulin dependent diabetes mellitus and/or impaired glucose tolerance.
  • the compounds of formula (I) can be manufactured by the methods given below, by the methods given in the Examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to the person skilled in the art. Starting materials are either commercially available or can be prepared by methods analogous to the methods given below or in the Examples or by methods known in the art.
  • DPP-IV inhibitors Activity of DPP-IV inhibitors are tested with natural human DPP-IV derived from a human plasma pool or with recombinat human DPP-IV.
  • Human citrate plasma from different donors is pooled, filterted through a 0.2 micron membrane under sterile conditions and ahquots of 1 ml are shock frozen and stored at -120°C until used.
  • colorimetric DPP-IV assay 5 to 10 ⁇ l human plasma and in the fluorometric assay 1.0 ⁇ l of human plasma in a total assay volume of 100 ⁇ l is used as an enzyme source.
  • Human DPP-IV is expressed and purified from the cultur medium using conventional column chromatography including size exclusion and anion and cation chromatography. The purity ofthe final enzyme preparation of Coomassie blue SDS-PAGE is > 95 %.
  • the colorimetric DPP-IV assay 20 ng rec.-h DPP-IV and in the fluorometric assay 2 ng rec-h DPP-IV in a total assay volume of 100 ⁇ l is used as an enzyme source.
  • Ala-Pro-7-amido-4-trifluoromethylcoumarin (Calbiochem No 125510) is used as a substrate.
  • a 20 mM stock solution in 10 % DMF/H 2 O is stored at - 20°C until use.
  • IC50 determinations a final substrate concentration of 50 ⁇ M is used.
  • assays to determine kinetic parameters as Km, Vmax, Ki the substrate concentration is varied between 10 ⁇ M and 500 ⁇ M.
  • H-Ala-Pro-pNA.HCl (Bachem L-1115) is used as a substrate.
  • a 10 mM stock solution in 10% MeOH/H 2 O is stored at -20oC until use.
  • IC50 determinations a final substrate concentration of 200 ⁇ M is used.
  • assays to determine kinetic parameters as Km, Vmax, Ki the substrate concentration is varied between 100 ⁇ M and 2000 ⁇ M.
  • Fluorescence is detected in a Perkin Elmer Luminescence Spectrometer LS 50B at an excitation wavelength of 400 nm and an emission wavelength of 505 nm continuously every 15 seconds for 10 to 30 minutes. Initial rate constants are calculated by best fit linear regression.
  • DPP-IV activity assays are performed in 96 well plates at 37°C in a total assay volume of 100 ⁇ l.
  • the assay buffer consists of 50 mM Tris/HCl pH 7.8 containing 0.1 mg/ml BSA and 100 mM NaCl.
  • Compounds are with (10 minutes at 37°C) and without preincubation with the enzyme. Enzyme reactions are started with substrate application follwed by immediate mixing.
  • IC50 determinations of test compounds are calculated by non-linear best fit regression of the DPP-IV inhibition of at least 5 different compound concentrations.
  • Kinetic parameters ofthe enzyme reaction are calculated at at least 5 different substrate concentrations and at least 5 different test compound concentrations.
  • the preferred compounds ofthe present invention exhibit IC50 values of 1 nM to 10 ⁇ M, more preferrably of 1 - 100 nM, as shown in the following table:
  • the compounds of formula I and/or their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical preparations for enteral, parenteral or topical administration. They can be administered, for example, perorally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions or infusion solutions, or topically, e.g. in the form of ointments, creams or oils. Oral administration is preferred.
  • the production ofthe pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled in the art by bringing the described compounds of formula I and/or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
  • Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials.
  • lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragees and hard gelatine capsules.
  • Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers might, however, be required in the case of soft gelatine capsules).
  • Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like.
  • Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils.
  • Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols.
  • Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.
  • Usual stabilizers preservatives, wetting and emulsifying agents, consistency- improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.
  • the dosage ofthe compounds of formula I can vary within wide limits depending on the disease to be controlled, the age and the individual condition ofthe patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 to 1000 mg, especially about 1 to 100 mg, comes into consideration. Depending on severity ofthe disease and the precise pharmacokinetic profile the compound could be administered with one or several daily dosage units, e.g. in 1 to 3 dosage units.
  • the pharmaceutical preparations conveniently contain about 1-500 mg, preferably 1-100 mg, of a compound of formula I.
  • 2-Thiophen-3-ylmethylene-malononitrile was prepared from 3-thiophenecarbaldehyde as a solid (0.4g, 21%).
  • Benzamidine (48mg, 0.4mmol) and potassium carbonate (97mg, 0.7mmol) were placed in a reaction vial and suspended in 2ml MeOH.
  • 2-(2,4-dimethyl-benzylidene)-malononitrile (87mg, 0.48mmol) was added, the vial was stoppered and shaken first for 30min at r.L, then for 3h at 60°C. After cooling, the mixture was filtered and the filtrate was evaporated in a vacuum zentrifuge (45°C). The residue was dissolved in 2ml of acetone, 63mg (0.4mmol) KMnO 4 was added, and the mixture was shaken for 2h at rt.
  • Example 84
  • Film coated tablets containing the following ingredients can be manufactured in a conventional manner:
  • the active ingredient is sieved and mixed with microcrystalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidon in water.
  • the granulate is mixed with sodium starch glycolate and magesium stearate and compressed to yield kernels of 120 or 350 mg respectively.
  • the kernels are lacquered with an aq. solution / suspension ofthe above mentioned film coat.
  • Capsules containing the following ingredients can be manufactured in a conventional manner:
  • the components are sieved and mixed and filled into capsules of size 2.
  • Injection solutions can have the following composition:
  • Water for injection solutions ad 1.0 ml
  • the active ingredient is dissolved in a mixture of polyethylene glycol 400 and water for injection (part).
  • the pH is adjusted to 5.0 by acetic acid.
  • the volume is adjusted to 1.0 ml by addition ofthe residual amount of water.
  • the solution is filtered, filled into vials using an appropriate overage and sterilized.
  • Soft gelatin capsules containing the following ingredients can be manufactured in a conventional manner:
  • the active ingredient is dissolved in a warm melting ofthe other ingredients and the mixture is filled into soft gelatin capsules of appropriate size.
  • the filled soft gelatin capsules are treated according to the usual procedures.
  • Sachets containing the following ingredients can be manufactured in a conventional manner:
  • Microcristalline cellulose (AVICEL PH 102) 1400.0 mg
  • Flavoring additives 1.0 mg
  • the active ingredient is mixed with lactose, microcrystalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidon in water.
  • the granulate is mixed with magnesium stearate and the flavouring additives and filled into sachets.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4 and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

Description

Novel Pyridin- and Pyrimidin-Derivatives
The present invention is concerned with pyridin- and pyrimidin-derivatives, their manufacture and their use as medicaments. In particular, the invention relates to compounds ofthe formula (I)
Figure imgf000002_0001
wherein
X is N or C-R5;
R1 and R2 are independently hydrogen or lower alkyl;
R3 is heterocyclyl; heterocyclyl mono-, di-, or tri-substituted, independently, by lower alkyl, perfluoro-lower alkyl, amino, lower alkoxy or halogen; aryl; or aryl mono-, di-, or tri-substituted, independently, by halogen, lower alkyl, amino, lower alkoxy or perfluoro-lower alkyl;
R4 is lower alkyl; lower alkoxy; lower alkylthio; heterocyclyl; heterocyclyl mono-, di-, or tri-substituted, independently, by lower alkyl, lower alkoxy, perfluoro-lower alkyl, amino or halogen; aryl; aryl mono-, di-, or tri-substituted, independently, by lower alkyl, lower alkoxy, halogen, amino, or perfluoro-lower alkyl; aryloxy lower alkyl or cycloalkyl;
R5 is hydrogen or lower alkyl; and pharmaceutically acceptable salts thereof.
Bro / 28.11.02 The enzyme dipeptidyl peptidase IV (EC.3.4.14.5, abbreviated in the following as DPP-IN) is involved in the regulation ofthe activities of several hormones. In particular DPP-IV is degrading efficiently and rapidly glucagon like peptide 1 (GLP-1), which is one ofthe most potent stimulator of insulin production and secretion. Inhibiting DPP-IN would potentiate the effect of endogenous GLP-1, and lead to higher plasma insulin concentrations. In patients suffering from impaired glucose tolerance and type 2 diabetes mellitus, higher plasma insulin concentration would moderate the dangerous hyperglycaemia and accordingly reduce the risk of tissue damage. Consequently, DPP-IN inhibitors have been suggested as drug candidates for the treatment of impaired glucose tolerance and type 2 diabetes mellitus (e.g. Vilhauer, WO98/19998). Other related state of the art can be found in WO 99/38501, DE 19616486, DE 19834591, WO 01/40180, WO 01/55105, US 6110949, WO 00/34241 and US6011155.
We have found novel DPP-IV inhibitors that very efficiently lower plasma glucose levels. Consequently, the compounds ofthe present invention are useful for the treatment and/or prophylaxis of diabetes, particularly non-insulin dependent diabetes mellitus, and/or impaired glucose tolerance, as well as other conditions wherein the amplification of action of a peptide normally inactivated by DPP-IV gives a therapeutic benefit. Surprisingly, the compounds ofthe present invention can also be used in the treatment and/or prophylaxis of obesity Bowl disease, Colitis Ulcerosa, Morbus Crohn, and/or metabolic syndrome. Furthermore, the compounds ofthe present invention can be used as diuretic agents and for the treatment and/or prophylaxis of hypertension. Unexpectedly, the compounds ofthe present invention exhibit improved therapeutic and pharmacological properties compared to other DPP IV inhibitors known in the art, such as e.g. in context with pharmacokinetics and bioavailability.
Unless otherwise indicated, the following definitions are set forth to illustrate and define the meaning and scope ofthe various terms used to describe the invention herein.
In this specification the term "lower" is used to mean a group consisting of one to six, preferably of one to four carbon atom(s).
The term "halogen" refers to fluorine, chlorine, bromine and iodine, with fluorine, bromine and chlorine being preferred. Most preferred halogen is chlorine.
The term "alkyl", alone or in combination with other groups, refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to twenty carbon atoms, preferably one to sixteen carbon atoms, more preferably one to ten carbon atoms. The term "lower alkyl", alone or in combination with other groups, refers to a branched or straight-chain monovalent alkyl radical of one to six carbon atoms, preferably one to four carbon atoms. This term is further exemplified by radicals such as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, isobutyl, t-butyl, n-pentyl, 3-methylbutyl, n- hexyl, 2-ethylbutyl and the like. Preferable lower alkyl residues are methyl and ethyl, with methyl being especially preferred.
The term "perfluoro-lower alkyl" refers to a lower alkyl group wherein all ofthe hydrogens ofthe lower alkyl group are substituted or replaced by fluoro. Among the preferred perfluoro-lower alkyl groups are trifiuoromethyl, pentafluoroethyl and heptafluoropropyl, with trifiuoromethyl being especially preferred.
The term "alkoxy" refers to the group R'-O-, wherein R' is alkyl. The term "lower- alkoxy" refers to the group R'-O-, wherein R' is lower-alkyl. Examples of lower alkoxy groups are e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy and hexyloxy, with methoxy being especially preferred.
The term "lower alkylthio" refers to the group R'-S-, wherein R' is lower-alkyl as defined above.
The term "cycloalkyl" refers to a monovalent carbocyclic radical of three to six, preferably three to five carbon atoms. This term is further exemplified by radicals such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, with cyclopropyl being preferred.
The term "heterocyclyl" refers to a saturated, unsaturated or aromatic monovalent 5- to 7-membered monocyclic, 9-membered bicyclic or 13-membered tricyclic radical having at least one heteroatom selected from nitrogen, sulfur and oxygen, or a combination thereof. Examples of heterocyclyl residues are pyridyl, pyrimidinyl, furyl, thienyl, indolyl, benzo[l,3]dioxolyl, benzofuranyl, benzothiophenyl, dibenzofuranyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, oxatriazolyl, thiatriazolyl, pyridazyl, pyrimidinyl, pyrazinyl, pyrrolidinyl, azepanyl, and morpholino. Said heterocyclyl residues may be mono-, di- or tri-substituted, independently, by halogen, amino, perfluoro-lower alkyl, lower alkyl or lower alkoxy, preferably by lower alkyl or lower alkoxy.
The term "aryl" refers to an aromatic monovalent mono- or polycarbocyclic radical, such as phenyl and naphthyl, preferably phenyl, which may optionally be mono-, di- or tri-substituted, independently, by lower alkyl, lower alkoxy, halogen, amino or perfluoro- lower alkyl, preferably by lower alkyl, lower alkoxy and halogen.
The term "aryloxy lower alkyl" refers to an aryl residue as defined above attached to a lower alkylene group via an oxy radical, i.e. aryl-O-R, wherein R is lower alkylene. The term "pharmaceutically acceptable salts" embraces salts ofthe compounds of formula (I) with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid, phosphoric acid, citric acid, formic acid, maleic acid, acetic acid, fumaric acid, succinic acid, tartaric acid, methanesulphonic acid, salicylic acid, p- toluenesulphonic acid and the like, which are non toxic to living organisms. Preferred salts with acids are formates, maleates, citrates, hydrochlorides, hydrobromides and methanesulfonic acid salts, with hydrochlorides being especially preferred.
In one embodiment ofthe present invention, R1 is lower alkyl, with methyl and isopropyl being preferred. In a preferable embodiment, R1 is hydrogen.
In another embodiment ofthe present invention, R2 is lower alkyl, with methyl being preferred. In a preferable embodiment, R2 is hydrogen.
In one embodiment ofthe present invention, X is N. In another embodiment, X is C-R5. Preferable X is N.
In one embodiment, R3 is heterocyclyl, such as pyridyl, pyrimidinyl, furyl, thienyl, indolyl, benzo[l,3]dioxolyl, benzofuranyl, benzothiophenyl, dibenzofuranyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, oxatriazolyl, thiatriazolyl, pyridazyl, pyrazinyl, pyrrolidinyl, azepanyl and morpholino, which hterocyclyl residues may optionally mono-, di- or tri-substituted, independently, by lower alkyl, lower alkoxy, perfluoro-lower alkyl, amino or halogen, preferably by by lower alkyl, lower alkoxy or halogen. Preferred heterocyclyl residues R3 are unsubstituted thienyl and unsubstituted benzo[l,3]dioxolyl. In a preferable embodiment, R3 is aryl, preferably phenyl, optionally ortho-, meta- and/or para-, preferably ortho- and para- substituted, independently, by lower alkyl, lower alkoxy, halogen, amino or perfluoro-lower alkyl, preferably by halogen, lower alkyl, perfluoro- lower alkyl or lower alkoxy. Most preferable residue R3 is 2,4-dichloro-phenyl.
In one embodiment, R4 is aryl such as phenyl or naphthyl, with phenyl being preferred. Phenyl residues R4 may optionally be ortho-, meta- and/or pαr -substituted, independently, by halogen, amino, lower alkyl, perfluoro-lower alkyl or lower alkoxy, preferably by halogen, such as fluoro, by lower alkyl, such as methyl or lower alkoxy, such as methoxy. Naphthyl residues R4 are preferably unsubstituted or mono-substituted by lower alkoxy, such as methoxy. In another embodiment R4 is lower alkoxy, preferably methoxy. In still another embodiment R4 is lower alkyl. Preferable lower alkyl residues R4 are methyl and isopropyl. In another embodiment R4 is cycloalkyl, with cyclopropyl being preferred. In another embodiment R4 is lower alkylthio, preferably methylthio. In another embodiment R4 is heterocyclyl. Preferable heterocyclyl residues R4 are pyridyl, pyrimidinyl, furyl, thienyl, indolyl, benzo[l,3]dioxolyl, benzofuranyl, benzothiophenyl, dibenzofuranyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, oxatriazolyl, thiatriazolyl, pyridazyl, pyrimidinyl, pyrazinyl, pyrrolidinyl, azepanyl, and morpholino. More preferable are pyridyl, thienyl, indolyl, benzo[l,3]dioxolyl, benzofuranyl, benzothiophenyl, dibenzofuranyl, pyrrolidinyl, azepanyl and morpholino. The said heterocyclyl residues may optionally be mono-, di- or tri-substituted, preferably mono- or di- substituted, independently, by halogen, amino, perfluoro-lower alkyl, lower alkyl or lower alkoxy, preferably by lower alkyl or lower alkoxy. In still another embodiment, R4 is aryloxy lower alkyl. Preferable aryloxy lower alkyl is phenoxy lower alkyl, wherein the phenyl moiety is substituted by halogen. Most preferable aryloxy lower alkyl is 4-fluorophenoxymefhyl.
In one embodiment ofthe present invention, R5 is lower alkyl, with methyl being preferred. In another embodiment, R5 is hydrogen.
Preferred compounds in accordance with the present invention are those compounds of formula I, wherein X is N, R1 and R2 are hydrogen, R3 is an aryl residue as defined above, preferably a phenyl residue which is ortho- and pαr -substituted, independently, by lower alkyl, lower alkoxy, halogen, amino or perfluoro-lower alkyl, most preferably 2,4-dichloro-phenyl, and R4 is alkoxy, preferably methoxy, alkylthio, preferably methylthio, aryl, preferably a phenyl reside which may optionally be ortho-, meta- and/or pαra-substituted, independently, as defined above, preferanly by by halogen, such as fluoro, by lower alkyl, such as methyl or lower alkoxy, such as methoxy, or a heterocyclyl residue as defined above, preferably pyrrolidinyl or azepanyl.
Compounds of formula (I) represent a preferred embodiment ofthe present invention and pharmaceutically acceptable salts of compounds of formula (I) individually also represent a preferred embodiment ofthe present invention.
Preferred compounds of general formula (I) are those selected from the group consisting of:
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-phenyl-pyrimidin-4-ylamine, 5-Aminomethyl-2-phenyl-6-p-tolyl-pyrimidin-4-ylamme,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-methoxy-phenyl)-pyrimidin-4- ylamine,
5-Aminomethyl-2-phenyl-6-o-tolyl-pyrimidin-4-ylamine, 5-Aminomefhyl-6-(2,4-difluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-m-tolyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,4,5-trimethoxy-phenyl)- pyrimidin-4-ylamine, 5-Aminomethyl-6-(2,4-dimethyl-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,5-dimethoxy-phenyl)-pyrimidin- 4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-fluoro-phenyl)-pyrimidin-4- ylamine, 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-fluoro-phenyl)-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-methoxy-l-methyl-lH-indol-6- yl) -pyrimidin-4-ylamine,
5-Aminomethyl-2-benzofuran-2-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(lH-indol-2-yl)-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-m-tolyl-pyrimidin-4-ylamine,
2-(4-Amino-3-methoxy-phenyl)-5-aminomethyl-6-(2,4-dichloro-phenyl)- pyrimidin-4-ylamine,
5-Aminomethyl-2-azepan-l-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,4-difluoro-phenyl)-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-pyrrolidin-l-yl-pyrimidin-4-ylamine, 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-methylsulfanyl-pyrimidin-4-ylamine,
5-Ammomethyl-6-(2,4-dichloro-phenyl)-2-(3,4-dimethoxy-phenyl)-pyrimidin- 4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-thiophen-2-yl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(2-fluoro-phenyl)-pyrimidin-4- ylamine,
5-Aminomefhyl-2-(4-chloro-phenyl)-6-(2,4-dichloro-phenyl)-pyrimidin-4- ylamine, 5-Ammomethyl-6-(2,4-dichloro-phenyl)-2-methoxy-pyrimidin-4-ylamine,
5-Aminomethyl-2-cyclopropyl-6-phenyl-pyrimidin-4-ylamine5-Aminomethyl-6- (2,4-dichloro-phenyl)-2-p-tolyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-methoxy-phenyl)-pyrimidin-4- ylamine,
5-Aminomethyl-2-benzo [ 1,3] dioxol-5-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-trifluoromethyl-phenyl)- pyrimidin-4-ylamine, 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-morpholin-4-yl-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-trifluoromethyl-phenyl)- pyrimidin-4-ylamine,
5-Aminomethyl-2-(3-chloro-phenyl)-6-(2,4-dichloro-phenyl)-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-methyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-naphthalen-2-yl-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-naphthalen-l-yl-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-methoxy-phenyl)-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,5-difluoro-phenyl)-pyrimidin-4- ylamine, 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(2-methoxy-phenyl)-pyrimidin-4- ylamine,
5-Aminomethyl-6-(4-ethyl-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-isopropyl-pyrimidin-4-ylamine,
5-Aminomethyl-2-(2-chloro-4-fluoro-phenyl)-6-(2,4-dichloro-phenyl)- pyrimidin-4-ylamine,
5-Aminomethyl-2-benzo[b]thiophen-2-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4- ylamine, 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(6-methoxy-naphthalen-2-yl)- pyrimidin-4-ylamine,
5-Aminomethyl-2-phenyl-6-m-tolyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(4-chloro-phenyl)-2-phenyl-pyrimidin-4-ylamine, 5-Aminomethyl-2-phenyl-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-o-tolyl-pyrimidin-4-ylamine,
5-Aminomethyl-2-(3,5-bis-trifluoromethyl-phenyl)-6-(2,4-dichloro-phenyl)- pyrimidin-4-ylamine, 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-fluoro-phenoxymethyl)- pyrimidin-4-ylamine,
5-Aminomethyl-6-(2-chloro-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2-bromo-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-2-dibenzofuran-2-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-bis-trifluoromethyl-phenyl)-2-phenyl-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2-fluoro-4-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dimethoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine, 5-Aminomethyl-2-(lH-indol-2-yl)-6-phenyl-pyrimidm-4-ylamine,
5-Aminomethyl-6-benzo [1,3] dioxol-5-yl-2-cyclopropyl-pyrimidin-4-ylamine, 5-Aminomethyl-6-(2-fluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine, 5-Aminomethyl-2-phenyl-6-(2-trifluoromethyl-phenyl)-pyrimidin-4-ylamine, 5-Aminomethyl-2-benzofuran-2-yl-6-phenyl-pyrimidin-4-ylamine, 5-Aminomethyl-6-(4-fluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-2-(3,4-dimethoxy-phenyl)-6-phenyl-pyrimidin-4-ylamine, 5-Aminomethyl-6-phenyl-2-pyridin-4-yl-pyrimidin-4-ylamine, 5-Aminomethyl-6-(3-chloro-phenyl)-2-phenyl-pyrimidin-4-ylamine, 5-Aminomethyl-6-phenyl-2-thiophen-2-yl-pyrimidin-4-ylamine, 5-Aminomethyl-6-(3-fluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine, 5-Aminomethyl-2,6-diphenyl-pyrimidin-4-ylamine,
5-Aminomethyl-6- (4-mefhoxy-phenyl) -2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-2-phenyl-6-thiophen-3-yl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(3-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine, 6-(2,4-Dichloro-phenyl)-5-methylaminomethyl-2-phenyl-pyrimidin-4-ylamine,
3-Aminomethyl-4-(2,4-dichloro-phenyl)-6-phenyl-pyridin-2-ylamine,
3-Aminomethyl-4-(2,4-dichloro-phenyl)-5-methyl-6-phenyl-pyridin-2-ylamine,
[5-Aminomefhyl-6-(4-chloro-phenyl)-2-pyridin-3-yl-pyrimidin-4-yl] -methyl- amine, 5-Aminomethyl-6-benzo[l,3]dioxol-5-yl-2-(4-methoxy-phenyl)-pyrimidin-4- ylamine,
5-Aminomethyl-6-benzo [1,3] dioxol-5-yl-2-phenyl-pyrimidin-4-ylamine,
[5-Aminomethyl-6-(4-chloro-phenyl)-2-pyridin-3-yl-pyrimidin-4-yl]-isopropyl- amine, (5-Aminomethyl-2,6-diphenyl-pyrimidin-4-yl)-methyl-amine,
3-Aminomethyl-4-(4-chloro-phenyl)-5-methyl-6-phenyl-pyridin-2-ylamine,
3-Aminomethyl-4-(4-chloro-phenyl)-6-phenyl-pyridin-2-ylamine,
3-Aminomethyl-4,6-bis-(4-fluoro-phenyl)-pyridin-2-ylamine, and
3-Aminomethyl-4-benzo [ 1 ,3] dioxol-5-yl-6-phenyl-pyridin-2-ylamine,
and pharmaceutically acceptable salts thereof.
Compounds of formula I wherein X is C-R5, R5 is lower alkyl and R3 is ortho- substituted phenyl can exist in the form of optically pure enantiomers or as racemates. The invention embraces all of these forms.
It will be appreciated, that the compounds of general formula (I) in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.
The compounds ofthe present invention can be prepared as outlined in Reaction Schemes I and II below: Reaction Scheme I
Figure imgf000011_0001
IVa
Reaction Scheme II
Figure imgf000011_0002
The present invention also relates to a process for the manufacture of compounds of formula I. This process comprises the reduction of nitriles of formulae IV, IVa, IX and IXa to amines of formulae la and lc, respectively. This reduction can be performed according to methods known in the art. For example, the reduction can be carried out using a metal hydride such as lithium aluminum hydride in an inert solvent. Nitriles of formulae IV and IVa are known in the art or can be prepared from arylidene malononitriles of formula V and amidines VII by processes known in the art. For example, the reaction can be performed in the presence of a base such as potassium carbonate in an inert solvent such as methanol.
Nitriles of formula IX and IXa are known in the art or can be prepared by processes known in the art. One such process is the reaction of arylidene malononitriles of formula V and ketones of formula X. For example, the reaction can be performed by heating with ammonium acetate in an inert solvent such as methanol.
Arylidene malononitriles of formula V are known in the art or can be prepared by processes known in the art, for instance by reaction of aromatic aldehydes VI with malononitrile in the presence of a base such as piperidine.
Amidines of formula VII are known in the art or can be prepared by processes known in the art. For instance, amidines of formula VII can be prepared from nitriles VIII by a process known in the art as the Pinner reaction.
Compounds of formulae lb and Id can be prepared from corresponding compounds of formulae la and lc, respectively, by an alkylation process known in the art (Bar-Haim, G.; Kol, M. Tetrahedron Lett. 1998, 39, 2663).
The invention further relates to compounds of formula (I) as defined above, when manufactured according to a process as defined above.
As described above, the compounds of formula (I) ofthe present invention can be used as medicaments for the treatment and/or prophylaxis of diseases which are associated with DPP IV such as diabetes, particularly non-insulin dependent diabetes mellitus, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn, obesity, and/or metabolic syndrome , preferably non-insulin dependent diabetes mellitus and/or impaired glucose tolerance. Furthermore, the compounds ofthe present invention can be used as diuretic agents or for the treatment and/or prophylaxis of hypertension.
The invention therefore also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable carrier and/or adjuvant.
Further, the invention relates to compounds as defined above for use as therapeutic active substances, particularly as therapeutic active substances for the treatment and/or prophylaxis of diseases which are associated with DPP IV such as diabetes, particularly non-insulin dependent diabetes mellitus, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn, obesity, and/or metabolic syndrome, preferably for use as therapeutic active substances for the treatment and/or prophylaxis of non-insulin dependent diabetes mellitus and/or impaired glucose tolerance. Furthermore, the invention relates to compounds as defined above for use as diuretic agents or for use as therapeutic active substances for the treatment and/or prophylaxis of hypertension.
In another embodiment, the invention relates to a method for the treatment and/or prophylaxis of diseases which are associated with DPP IV such as diabetes, particularly non-insulin dependent diabetes mellitus, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn, obesity, and/or metabolic syndrome, preferably for the treatment and/or prophylaxis of non-insulin dependent diabetes mellitus and/or impaired glucose tolerance, which method comprises administering a compound as defined above to a human being or animal. Furthermore, the invention relates to a method for the treatment and/or prophylaxis as defined above, wherein the disease is hypertension or wherein a diuretic agent has a beneficial effect.
The invention further relates to the use of compounds as defined above for the treatment and/or prophylaxis of diseases which are associated with DPP IV such as diabetes, particularly non-insulin dependent diabetes mellitus, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn, obesity, and/or metabolic syndrome, preferably for the treatment and/or prophylaxis of non-insulin dependent diabetes mellitus and/or impaired glucose tolerance. Furthermore, the invention relates to the use as defined above, wherein the disease is hypertension or to the use as diuretic agent.
In addition, the invention relates to the use of compounds as defined above for the preparation of medicaments for the treatment and/or prophylaxis of diseases which are associated with DPP IV such as diabetes, particularly non-insulin dependent diabetes mellitus, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn, obesity, and/ or metabolic syndrome, preferably for the treatment and/or prophylaxis of non-insulin dependent diabetes mellitus and/or impaired glucose tolerance. Such medicaments comprise a compound as defined above. Furthermore, the invention relates to the use as defined above, wherein the disease is hypertension or the use for the preparation of diuretic agents.
In context with the methods and uses defined above, the following diseases relate to a preferred embodiment: diabetes, particularly non-insulin dependent diabetes mellitus, impaired glucose tolerance, obesity, and/or metabolic syndrome, preferably non-insulin dependent diabetes mellitus and/or impaired glucose tolerance.
The compounds of formula (I) can be manufactured by the methods given below, by the methods given in the Examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to the person skilled in the art. Starting materials are either commercially available or can be prepared by methods analogous to the methods given below or in the Examples or by methods known in the art.
The following tests were carried out in order to determine the activity ofthe compounds of formula I.
Activity of DPP-IV inhibitors are tested with natural human DPP-IV derived from a human plasma pool or with recombinat human DPP-IV. Human citrate plasma from different donors is pooled, filterted through a 0.2 micron membrane under sterile conditions and ahquots of 1 ml are shock frozen and stored at -120°C until used. In the colorimetric DPP-IV assay 5 to 10 μl human plasma and in the fluorometric assay 1.0 μl of human plasma in a total assay volume of 100 μl is used as an enzyme source. The cDNA of the human DPP-IV sequence of amino acid 31 - to 766, restricted for the N- terminus and the transmembrane domain, is cloned into pichia pastoris. Human DPP-IV is expressed and purified from the cultur medium using conventional column chromatography including size exclusion and anion and cation chromatography. The purity ofthe final enzyme preparation of Coomassie blue SDS-PAGE is > 95 %. In the colorimetric DPP-IV assay 20 ng rec.-h DPP-IV and in the fluorometric assay 2 ng rec-h DPP-IV in a total assay volume of 100 μl is used as an enzyme source.
In the fluorogenic assay Ala-Pro-7-amido-4-trifluoromethylcoumarin (Calbiochem No 125510) is used as a substrate. A 20 mM stock solution in 10 % DMF/H2O is stored at - 20°C until use. In IC50 determinations a final substrate concentration of 50 μM is used. In assays to determine kinetic parameters as Km, Vmax, Ki, the substrate concentration is varied between 10 μM and 500 μM.
In the colorimetric assay H-Ala-Pro-pNA.HCl (Bachem L-1115) is used as a substrate. A 10 mM stock solution in 10% MeOH/H2O is stored at -20oC until use. In IC50 determinations a final substrate concentration of 200 μM is used. In assays to determine kinetic parameters as Km, Vmax, Ki, the substrate concentration is varied between 100 μM and 2000 μM.
Fluorescence is detected in a Perkin Elmer Luminescence Spectrometer LS 50B at an excitation wavelength of 400 nm and an emission wavelength of 505 nm continuously every 15 seconds for 10 to 30 minutes. Initial rate constants are calculated by best fit linear regression.
The absorption of pNA liberated from the colorimetric substrate is detected in a Packard SpectraCount at 405 nM continuosly every 2 minutes for 30 to 120 minutes. Initial rate constants are calculated by best fit linear regression. DPP-IV activity assays are performed in 96 well plates at 37°C in a total assay volume of 100 μl. The assay buffer consists of 50 mM Tris/HCl pH 7.8 containing 0.1 mg/ml BSA and 100 mM NaCl. Test compounds -are solved in 100 % DMSO, diluted to the desired concentration in 10% DMSO/H2O. The final DMSO concentration in the assay is 1 % (v/v). At this concentration enzyme inactivation by DMSO is < 5%. Compounds are with (10 minutes at 37°C) and without preincubation with the enzyme. Enzyme reactions are started with substrate application follwed by immediate mixing.
IC50 determinations of test compounds are calculated by non-linear best fit regression of the DPP-IV inhibition of at least 5 different compound concentrations. Kinetic parameters ofthe enzyme reaction are calculated at at least 5 different substrate concentrations and at least 5 different test compound concentrations.
The preferred compounds ofthe present invention exhibit IC50 values of 1 nM to 10 μM, more preferrably of 1 - 100 nM, as shown in the following table:
Figure imgf000015_0001
The compounds of formula I and/or their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical preparations for enteral, parenteral or topical administration. They can be administered, for example, perorally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions or infusion solutions, or topically, e.g. in the form of ointments, creams or oils. Oral administration is preferred. The production ofthe pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled in the art by bringing the described compounds of formula I and/or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials. Thus, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragees and hard gelatine capsules. Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers might, however, be required in the case of soft gelatine capsules). Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like. Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils. Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols. Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.
Usual stabilizers, preservatives, wetting and emulsifying agents, consistency- improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.
The dosage ofthe compounds of formula I can vary within wide limits depending on the disease to be controlled, the age and the individual condition ofthe patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 to 1000 mg, especially about 1 to 100 mg, comes into consideration. Depending on severity ofthe disease and the precise pharmacokinetic profile the compound could be administered with one or several daily dosage units, e.g. in 1 to 3 dosage units. The pharmaceutical preparations conveniently contain about 1-500 mg, preferably 1-100 mg, of a compound of formula I.
The following Examples serve to illustrate the present invention in more detail. They are, however, not intended to limit its scope in any manner.
Examples
Abbreviations:
MS = mass spectrometry, aq = aqueous, r.t. = room temperature, THF = tetrahydrofuran, TFA = trifluoroacetic acid, NMR = nuclear magnetic resonance spectroscopy, DMF = dimethylformamide, DMSO = dimethylsulfoxide, DCM = dichloromethane.
Example 1
Synthesis of aryl methylidene malononitriles (Procedure 1 in Reaction Scheme I)
2-(2,4-Dichloro-benzylidene)-malononitrile
Under an atmosphere of argon, 2,4-dichlorobenzaldehyde (30.00g, 171mmol) and malononitrile (13.59g, 206mmol) were suspended in 1-butanol (350ml). After stirring for 15min, 8 drops of piperidine were added at room temperature. After stirring for an additional 3h, diethyl ether was added. The precipitate was filtered and washed with diethyl ether and hexane to give the title compound, MS: m/e = 222.8 (M+), as a colorless solid (35.34g, 92%).
1H-NMR (300MHz, d6-DMSO, 25°C): δ(ppm) = 7.45 (IH, m), 7.59 (IH, m), 8.18 (2H, m).
The following methylidene malononitriles were prepared in analogy to the procedure described above:
2- (4-Trifluoromethyl-benzylidene) -malononitrile, MS: m/e = 222.9 (M+), was prepared from 4- trifiuoromethyl benzaldehyde as a solid (1.35g, 48%).
2-(2-Methyl-benzylidene)-malononitrile, MS: m/e = 168.8 (M+), was prepared from ortho- tolyl aldehyde as a solid (1.99g, 73%).
2- (3 -Methoxy-benzylidene) -malononitrile, MS: m/e = 184.7 (M+), was prepared from met -anisaldehyde as a solid (1.71g, 55%).
2- (2,4-Dimethoxy-benzylidene) -malononitrile, MS: m/e = 214.8 (M+), was prepared from 2,4-dimethoxybenzaldehyde as a solid (2.48g, 96%). 2-(2,4-Dimethyl-benzylidene)-malononitrile, MS: m/e = 182.8 (M+), was prepared from 2,4-dimethylbenzaldehyde as a solid (1.75g, 63%).
2-(2-Fluoro-4-methoxy-benzylidene)-malononitrile, MS: m/e = 202.7 (M+), was prepared from 2-fluoro-4-methoxybenzaldehyde as a solid (1.56g, 64%).
2- (2,4-Difluoro-benzylidene) -malononitrile, MS: m/e = 190.7 (M+), was prepared from 2,4-difluorobenzaldehyde as a solid (2.38g, 96%).
2-(4-Fluoro-benzylidene)-malononitrile, MS: m/e = 172.8 (M+), was prepared from 4- fluorobenzaldehyde as a solid (1.87g, 84%).
2-(2-Bromo-benzylidene)-malononitrile, MS: m/e = 233.8 (M+), was prepared from 2- bromobenzaldehyde as a solid (1.59g, 57%).
2-(2,4-Bis-trifluoromethyl-benzylidene)-malononitrile, MS: m/e = 290.7 (M+), was prepared from 2,4-bis(trifluoromethyl)benzaldehyde as a solid (1.10g, 92%).
2-(2-Fluoro-benzylidene)-malononitrile, MS: m/e = 172.9 (M+), was prepared from 2- fluorobenzaldehyde as a solid (1.55g, 75%).
2-Thiophen-3-ylmethylene-malononitrile was prepared from 3-thiophenecarbaldehyde as a solid (0.4g, 21%).
2-(3-Fluoro-benzylidene)-malononitrile, MS: m/e = 160.8 (M+), was prepared from 3- fluorobenzaldehyde as a solid (1.72g, 83%).
2-(3-Methyl-benzylidene)-malononitrile, MS: m/e = 168.7 (M+), was prepared from m- tolylaldehyde as a solid (0.74g, 37%).
2- (2-Trifluoromethyl-benzylidene) -malononitrile, MS: m/e = 222.8 (M+), was prepared from 2-trifluoromethylbenzaldehyde as a solid (2.20g, 83%).
2-Benzo[l,3]dioxol-5-ylmethylene-malononitrile, MS: m/e = 189.8 (M+), was prepared from piperonal as a solid (19.4g, 98%).
2-(4-Methyl-benzylidene)-malononitrile, MS: m/e = 168.9 (M+), was prepared from 4- methylbenzaldehyde as a solid.
2- (4-Chloro-benzylidene) -malononitrile, MS: m/e = 188.7 (M+), was prepared from 4- chlorobenzaldehyde as a solid. 2-(2-Methoxy-benzylidene)-malononitrile, MS: m/e = 184.8 (M+), was prepared from 2- methoxybenzaldehyde as a solid.
2-(2-Chloro-benzylidene)-malononitrile, MS: m/e = 188.9 (M+), was prepared from 2- chlorobenzaldehyde as a solid.
2-(3-Chloro-benzylidene)-malononitrile, MS: m/e = 188.9 (M+),was prepared from 3- chlorobenzaldehyde as a solid.
2- (4-Methoxy-benzylidene) -malononitrile, MS: m/e = 184.7 (M+), was prepared from 4- methoxybenzaldehyde as a solid.
2-Thiophen-3-ylmethylene-malononitrile, MS: m/e = 160.8 (M+), was prepared from 3- thiophenecarbaldehyde as a solid.
2-(3-Mefhoxy-benzylidene)-malononitrile, MS: m/e = 184.8 (M+), was prepared from 3- methoxybenzaldehyde as a solid.
Example 2
Synthesis of Benzamidines
(Procedure 2 in Reaction Scheme I)
3 ,5 -Dimethoxy-b enzamidine
Dry HCl gas was bubbled through a cooled (-15°C) solution of 3,5-dimethoxybenzonitrile (1.50g, 9.20mmol) for 30 minutes. The reaction mixture was placed in a refrigerator overnight. After evaporation ofthe solvent, a white solid was obtained which was dissolved in ethanol. 9.2ml of a 2molar solution of ammonia in Methanol was added and the reaction mixture was stirred at room temperatur overnight. After evaporation ofthe solvent, the title compound, MS: m/e = 181.2 (M+H+), (1.21g, 71%) was obtained by chromatographic purification ofthe residue (silica gel, MeOH, DCM).
1H-NMR (300MHz, d6-DMSO, 25°C): δ(ppm) = 3.80 (6H, s), 6.82 (IH, t, J = 2Hz), 7.05 (2H, t, J = 2Hz), 9.35 (3H, bs).
The following benzamidines were prepared in analogy to the procedure described above:
3 -Trifluoromethyl-b enzamidine, MS: m/e = 189.2 (M+H+), was prepared from 3- trifluoromethyl-benzonitrile as a solid (1.14g, 69%). 2-Methoxy-benzamidine, MS: m/e = 151.2 (M+H+), was prepared from 2- methoxybenzonitrile as a solid (113mg, 7%).
3,4,5-Trimethoxy-benzamidine, MS: m/e = 211.3 (M+H+), was prepared from 3,4,5- trimethoxy-benzaldehyde as a solid.
3,4 -Dimethoxy-benzamidine, MS: m/e = 181.2 (M+H+), was prepared from 3,4- dimethoxy-benzaldehyde as a solid.
Thiophene-2-carboxamidine, MS: m/e = 127.1 (M+H+), was prepared from thiophene-3- carbonitrile as a solid.
2-Fluorobenzamidine, MS: m/e = 139.2 (M+H+), was prepared from 2-fluorobenzonitrile as a solid.
4- Chlorob enzamidine, MS: m/e = 154.2 (M+H+), was prepared from 4-chlorobenzonitrile as a solid.
4-Methylbenzamidine, MS: m/e = 135.1 (M+H+), was prepared from 4-methylbenzonitrile as a solid.
4-Methoxybenzamidine, MS: m/e = 151.3 (M+H+), was prepared from 4- methoxybenzonitrile as a solid.
Benzo[l,3]dioxole-5-carboxamidine, MS: m/e = 165.2 (M+H+), was prepared from benzo[l,3]dioxole-5-carbonitrile as a solid.
Naphthalene- 1-carboxamidine, MS: m/e = 171.2 (M+H+), was prepared from naphthalene- 1-carbonitrile as a solid.
3-Methoxy-benzamidine, MS: m/e = 151.3 (M+H+),was prepared from 3-methoxy- benzonitrile as a solid.
2-Chloro-4-fluorobenzamidine, MS: m/e = 173.1 (M+H+), was prepared from 3-chloro-4- fluorobenzonitrile as a solid.
2-Methylbenzamidine, MS: m/e = 134.1 (M+H+), was prepared from 2-methyl- benzonitrile as a solid.
lH-indole-2-carboxamidine, MS: m/e = 160.2 (M+H+), was prepared from lH-indole-2- carbonitrile as a solid. Benzofuran-2-carboxamidine, MS: m/e = 161.3 (M+H+), was prepared from benzofuran- 2-carbonitrile as a solid.
Isonicotinamidine, MS: m/e = 122.2 (M+H+), was prepared from 4-cyanopyridine as a solid.
Example 3
Synthesis of 4-Amino-pyrimidine-5-carbonitriles (Procedure 3 in Reaction Scheme I)
4-Amino-6-(2,4-dichloro-phenyl)-2-phenyl-pyrimidine-5-carbonitrile
Potassium carbonate (4.34g, 31.4mmol) and benzamidine (2.59g, 21.5mmol) were added at to a suspension of 2-(2,4-dichloro-benzylidene)-malononitrile (4g, 17.9mmol) in methanol. The yellow mixture was stirred for lh at room temperature and then heated to reflux for an additional 2 h. After cooling, the solvent was removed at reduced pressure, the residue was taken up in ethyl acetate/ice. The organic phase was separated, washed with water, and dried over sodium sulfate. The solvent was evaporated, the orange residue was taken up in acetone, and 1.91g potassium manganate was added. After stirring for 90min, the reaction mixture was filtered through decalite and evaporated. Purification by flash chromatography (silica gel, EtOAc / hexanes) afforded the title compound, MS: m/e = 340.8 (M+), as a solid (2.63g, 43%).
1H-NMR (300MHz, d6-DMSO, 25°C): δ(ppm) = 7.48-7.60 (3H, m), 7.62-7.68 (2H, m), 7.77 (IH, s), 8.30 (2H, bs), 8.60-8.70 (2H, m).
The following 4-Amino-pyrimidine-5-carbonitriles were prepared in analogy to the procedure described above:
4-Amino-6-benzo[l,3]dioxol-5-yl-2-phenyl-pyrimidine-5-carbonitrile, MS: m/e = 315.9 (M+), was prepared from 2-benzo[l,3]dioxol-5-ylmethylene-malononitrile as a solid (629mg, 23%).
4-Amino-6-benzo[l,3]dioxol-5-yl-2-(4-methoxy-phenyl)-pyrimidine-5-carbonitrile, MS: m/e = 346.2 (M+), was prepared from 2-benzo[l,3]dioxol-5-ylmethylene-malononitrile and -Methoxybenzamidine as a solid (78mg, 26%). 4-Amino-2-phenyl-6-(4-trifluoromethyl-phenyl)-pyrimidine-5-carbonitrile, MS: m/e = 340.1 (M+), was prepared from 2-(4-trifluoromethyl-benzylidene)-malononitrile as a solid (312mg, 20%).
4-Amino-2-phenyl-6-o-tolyl-pyrimidine-5-carbonitrile, MS: m/e = 286.8 (M+H+), was prepared from 2- (2-methyl-benzylidene) -malononitrile as a solid (700mg, 22%).
4-Amino-6-(3-methoxy-phenyl)-2-phenyl-pyrimidine-5-carbonitrile, MS: m/e = 301.8(M+), was prepared from 2-(3-methoxy-benzylidene)-malononitrile as a solid (391mg, 15%).
4-Amino-2-phenyl-6-m-tolyl-pyrimidine-5-carbomtrile, MS: m/e = 286.1 (M+), was prepared from 2-(3-methyl-benzylidene)-malononitrile as a solid (515mg, 28%).
4-Amino-2-phenyl-6-p-tolyl-pyrimidine-5-carbonitrile, MS: m/e = 286.0 (M+), was prepared from 2- (4-methyl-benzylidene) -malononitrile as a solid (3.13g, 37%).
4-Amino-6-(2,4-dichloro-phenyl)-2-(3-methoxy-phenyl)-pyrimidine-5-carbonitrile, MS: m/e = 371.2 (M+H+), was prepared from 2-(2,4-dichloro-benzylidene)-malononitrile and 3-methoxybenzamidine as a solid (17mg, 32%).
4-Amino-6-(2,4-difluoro-phenyl)-2-phenyl-pyrimidine-5-carbonitrile was prepared from 2-(2,4-difluoro-benzylidene)-malononitrile as a solid (430mg, 88%).
4-Amino-6-(2,4-dichloro-phenyl)-2- -tolyl-pyrimidine-5-carbonitrile, MS: m/e = 308.1 (M+), was prepared from 2-(2,4-dichloro-benzylidene)-malononitrile and 3- methylbenzamidine as a solid ( 150mg, 87%).
4-Amino-6-(2,4-dichloro-phenyl)-2-(3,4,5-trimethoxy-phenyl)-pyrimidine-5- carbonitrile, MS: m/e = 430.0 (M+), was prepared from 2-(2,4-dichloro-benzylidene)- malononitrile and 3,4,5-trimethoxy-benzamidine as a solid (1.4g, 96%).
Example 4
Synthesis of 5-Aminomethyl-pyrimidin-4-ylamines (Procedure 4 in Reaction Scheme I)
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-phenyl-pyrimidin-4-ylamine
Figure imgf000024_0001
Under an atmosphere of argon, a solution of 4-Amino-6-(2,4-dichloro-phenyl)-2-phenyl- pyrimidine-5-carbonitrile (1.16g, 0.34mmol) in THF (6ml) was added slowly to a suspension of L-AIH4 in THF (3ml). After stirring for 2h at 40°C, the reaction mixture was cooled to -20°C and water (0.6ml) was added. After 15min, ethyl acetate was added and the mixture was filtered through Decalite. The organic phase was then separated, washed with water, and dried over sodium sulfate. Purification by flash chromatography (silica gel, methanol, dichloromethane) afforded the title compound, MS: m/e = 344.2 (M+), as a light yellow solid (0.446g, 40%).
1H-NMR (300MHz, d6-DMSO, 25°C): δ(ppm) = 3.35 (IH, d, J = 11Hz), 3.50 (IH, d, J = 11Hz), 7.28 (bs, 2H), 7.38-7.46 (3H, m), 7.50-7.58 (2H, m), 7.75 (IH, m), 8.20-8.30 (2H, m).
Example 5
5-Aminomethyl-2-phenyl-6-p-tolyl-pyrimidin-4-ylamine
Figure imgf000024_0002
The title compound, MS: m/e = 289.9 (M+), was prepared from 4-amino-2-phenyl-6-p- tolyl-pyrimidine-5-carbonitrile in analogy to the process described in Example 4 as a solid (190mg, 37%). Example 6
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-methoxy-phenyl)-pyrimidin-4-ylamine
Figure imgf000025_0001
The title compound, MS: m/e = 374.9 (M+), was prepared from 4-amino-6-(2,4-dichloro- phenyl)-2-(3-methoxy-phenyl)-pyrimidine-5-carbonitrile in analogy to the process described in Example 4 as a solid (1.5mg, 9%).
Example 7
5-Aminomethyl-2-phenyl-6-o-tolyl-pyrimidin-4-ylamine
Figure imgf000025_0002
The title compound, MS: m/e = 290.8 (M+H+), was prepared from 4-amino-2-phenyl-6-ø- tolyl-pyrimidine-5-carbonitrile in analogy to the process described in Example 4 as a solid (62mg, 31%).
Example 8
5-Aminomethyl-6-(2,4-difluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine
Figure imgf000025_0003
The title compound, MS: m/e = 312.1 (M+), was prepared from 4-amino-2-phenyl-6-o- tolyl-pyrimidine-5-carbonitrile in analogy to the process described in Example 4 as a solid (21mg, 10%).
Example 9
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-m-tolyl-pyrimidin-4-ylamine
Figure imgf000026_0001
The title compound, MS: m/e = 359.1 (M+H+), was prepared from 4-amino-6-(2,4- dichloro-phenyl)-2-m-tolyl-pyrimidine-5-carbonitrile in analogy to the process described in Example 4 as a solid ( 1.4mg, 92%).
Example 10
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,4,5-trimethoxy-phenyl)-pyrimidin-4- ylamine
Figure imgf000026_0002
The title compound, MS: m/e = 434.9 (M+), was prepared from 4-amino-6-(2,4-dichloro- phenyl)-2-(3,4,5-trimethoxy-phenyl)-pyrimidine-5-carbonitrile in analogy to the process described in Example 4 as a solid (164mg, 12%). Example 11
5-Aminomethyl-pyrimidin-4-ylamines by high-troughput synthesis from aryl methylidene malononitriles
(Procedure 5 in Reaction Scheme I)
5-Aminomethyl-6-(2,4-dimethyl-phenyl)-2-phenyl-pyrimidin-4-ylamine
Figure imgf000027_0001
Benzamidine (48mg, 0.4mmol) and potassium carbonate (97mg, 0.7mmol) were placed in a reaction vial and suspended in 2ml MeOH. 2-(2,4-dimethyl-benzylidene)-malononitrile (87mg, 0.48mmol) was added, the vial was stoppered and shaken first for 30min at r.L, then for 3h at 60°C. After cooling, the mixture was filtered and the filtrate was evaporated in a vacuum zentrifuge (45°C). The residue was dissolved in 2ml of acetone, 63mg (0.4mmol) KMnO4 was added, and the mixture was shaken for 2h at rt. The reaction mixture was then filtered and the filtrate evaporated in a vacuum zentrifuge (45°C). Purification ofthe re-dissolved (DMF, 1ml) residue by automated, preparative HPLC (YMC CombiPrep C18 column 50x20mm, solvent gradient 5-95% CH3CN in 0.1% TFA(aq) over 6.0min, λ = 230nm, flow rate 40ml/min) gave 22mg of an intermediate which was dissolved in THF (1ml) and added, under an atmosphere of argon, to a cooled (0°C) suspension of lOOmg of Lithium aluminim hydride in 1ml THF in a reaction vial. The raction mixture was shaken first for 2h at r.t. and subsequently for 4h at 40°C. Upon cooling, water was added carefully and the mixture was filtered. The filtrate was evaporated in a vacuum zentrifuge (45°C). Purification ofthe re-dissolved (DMF, 1ml) residue by automated, preparative HPLC (YMC CombiPrep C18 column 50x20mm, solvent gradient 5-95% CH3CN in 0.1% TFA(aq) over 6.0min, λ = 230nm, flow rate 40ml/min) gave 8mg (7%) ofthe title compound, MS: m/e = 304.9 (M+), as a solid. Example 12
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,5-dimethoxy-phenyl)-pyrimidin-4-ylamine
Figure imgf000028_0001
The title compound, MS: m/e = 405.4 (M+H+), was prepared from 3,5-dimethoxy- benzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 13
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-fluoro-phenyl)-pyrimidin-4-ylamine
Figure imgf000028_0002
The title compound, MS: m/e = 362.9 (M+H+), was prepared from 3-fluoro-benzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 14
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-fluoro-phenyl)-pyrimidin-4-ylamine
Figure imgf000028_0003
The title compound, MS: m/e = 362.9 (M+H+), was prepared from 4-fluoro-benzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 15
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-methoxy-l-methyl-lH-indol-6-yl)- pyrimidin-4-ylamine
Figure imgf000029_0001
The title compound, MS: m/e = 428.0 (M+H+), was prepared from 4-methoxy-l-methyl- lH-indole-6-carboxamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 16
5-Aminomethyl-2-benzofuran-2-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine
Figure imgf000029_0002
The title compound, MS: m/e = 385.3 (M+H+), was prepared from benzofuran-2- carboxamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 17
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(li:-r-indol-2-yl)-pyrimidin-4-ylamine
Figure imgf000029_0003
The title compound, MS: m/e = 383.9 (M+H+), was prepared from lH-indole-2- carboxamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 18
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-m-tolyl-pyrimidin-4-ylamine
Figure imgf000030_0001
The title compound, MS: m/e = 359.1 (M+H+), was prepared from 3 -methyl-b enzamidine and 2- (2,4-dichloro-benzylidene) -malononitrile in analogy to the process described in Example 11 as a solid.
Example 19
2-(4-Amino-3-methoxy-phenyl)-5-aminomethyl-6-(2,4-dichloro-phenyl)-pyrimidin-4- ylamine
Figure imgf000030_0002
The title compound, MS: m/e = 389.9 (M+H+), was prepared from 4-amino-3-methoxy- benzamidine and 2-(2,4-dichloro-behzylidene)-malononitrile in analogy to the process described in Example 11 as a solid. Example 20
5-Aminomethyl-2-azepan-l-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine
Figure imgf000031_0001
The title compound, MS: m/e = 366.0 (M+H+), was prepared from azepane-1- carboxamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 21
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,4-difluoro-phenyl)-pyrimidin-4-ylamine
Figure imgf000031_0002
The title compound, MS: m/e = 381.3 (M+H+), was prepared from 3,4-difluoro- benzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 22
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-pyrrolidin-l-yl-pyrimidin-4-ylamine
Figure imgf000031_0003
The title compound, MS: m/e = 337.8 (M+), was prepared from pyrrolidine-1- carboxamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 23
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-methylsulfanyl-pyrimidin-4-ylamine
Figure imgf000032_0001
The title compound, MS: m/e = 315.2 (M+), was prepared from 2-methyl-isothiourea and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 24
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,4-dimethoxy-phenyl)-pyrimidin-4-ylamine
Figure imgf000032_0002
The title compound, MS: m/e = 405.3 (M+H+), was prepared from 3,4-dimethoxy- benzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 25
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-thiophen-2-yl-pyrimidin-4-ylamine
Figure imgf000032_0003
The title compound, MS: m/e = 351.2 (M+H+), was prepared from thiophene-2- carboxamidine and 2- (2,4-dichloro-benzylidene) -malononitrile in analogy to the process described in Example 11 as a solid.
Example 26
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(2-fluoro-phenyl)-pyrimidin-4-ylamine
Figure imgf000033_0001
The title compound, MS: m/e = 363.0 (M+H+), was prepared from 2-fluorobenzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 27
5-Aminomethyl-2-(4-chloro-phenyl)-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine
Figure imgf000033_0002
The title compound, MS: m/e = 377.8 (M+), was prepared from 4-chloro-benzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 28
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-methoxy-pyrimidin-4-ylamine
Figure imgf000033_0003
The title compound, , MS: m/e = 337.8 (M+), was prepared from 2-methyl-isourea and 2- (2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 a solid.
Example 29
5-Aminomethyl-2-cyclopropyl-6-phenyl-pyrimidin-4-ylamine
Figure imgf000034_0001
The title compound, MS: m/e = 240.1 (M+), was prepared from cyclopropanecarboxamidine and 2 -benzylidene- malononitrile in analogy to the process described in Example 11 as a solid.
Example 30
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-Jp-tolyl-pyrimidin-4-ylamine
Figure imgf000034_0002
The title compound, MS: m/e = 358.2 (M+), was prepared from 4-methylbenzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 31
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-methoxy-phenyl)-pyrimidin-4-ylamine
Figure imgf000034_0003
The title compound, MS: m/e = 375.3 (M+H+), was prepared from 4- methoxybenzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 32
5-Aminomethyl-2-benzo[l,3]dioxol-5-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine
Figure imgf000035_0001
The title compound, MS: m/e = 388.2 (M+), was prepared from benzo[l,3]dioxole-5- carboxamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 33
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-trifluoromethyl-phenyl)-pyrimidin-4- ylamine
Figure imgf000035_0002
The title compound, MS: m/e = 412.9 (M+H+), was prepared from 3-trifluoromethyl- benzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid. Example 34
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-morpholin-4-yl-pyrimidin-4-ylamine
Figure imgf000036_0001
The title compound, MS: m/e = 353.9 (M+), was prepared from morpholine-4- carboxamidine and 2- (2,4-dichloro-benzylidene) -malononitrile in analogy to the process described in Example 11 as a solid.
Example 35
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-trifluoromethyl-phenyl)-pyrimidin-4- ylamine
Figure imgf000036_0002
The title compound, MS: m/e = 412.9 (M+H+), was prepared from 4-trifluoromethyl- benzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 36
5-Aminomethyl-2-(3-chloro-phenyl)-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine
Figure imgf000036_0003
The title compound, MS: m/e = 378.8 (M+H+), was prepared from 3-chlorobenzamidine and 2- (2,4-dichloro-benzylidene) -malononitrile in analogy to the process described in Example 11 as a solid.
Example 37
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-methyl-pyrimidin-4-ylamine
Figure imgf000037_0001
The title compound, MS: m/e = 282.9 (M+H+), was prepared from acetamidine and 2- (2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 38
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-naphthalen-2-yl-pyrimidin-4-ylamine
Figure imgf000037_0002
The title compound, MS: m/e = 394.9 (M+H+), was prepared from naphthalene-2- carboxamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid. Example 39
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-naphthalen-l-yl-pyrimidin-4-ylamine
Figure imgf000038_0001
The title compound, MS: m/e = 395.3 (M+H+), was prepared from naphthalene- 1- carboxamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 40
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-methoxy-phenyl)-pyrimidin-4-ylamine
Figure imgf000038_0002
The title compound, MS: m/e = 374.8 (M+), was prepared from 3-methoxybenzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 41
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,5-difluoro-phenyl)-pyrimidin-4-ylamine
Figure imgf000039_0001
The title compound, , MS: m/e = 380.9 (M+H+), was prepared from 3,5- difluorobenzamidine and 2- (2,4-dichloro-benzylidene) -malononitrile in analogy to the process described in Example 11 as a solid.
Example 42
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(2-methoxy-phenyl)-pyrimidin-4-ylamine
Figure imgf000039_0002
The title compound, MS: m/e = 374.8 (M+H+), was prepared from 2- methoxybenzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 43
5-Aminomethyl-6- (4- ethyl- phenyl) -2-phenyl-pyrimidin-4-ylamine
Figure imgf000039_0003
The title compound, MS: m/e = 304.8 (M+H+), was prepared from 2-(4-ethyl- benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 44
5-Aminomefhyl-6-(2,4-dichloro-phenyl)-2-isopropyl-pyrimidin-4-ylamine
Figure imgf000040_0001
The title compound, MS: m/e = 311.2 (M+H+), was prepared from isobutyramidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 45
5-Aminomethyl-2-(2-chloro-4-fluoro-phenyl)-6-(2,4-dichloro-phenyl)-pyrimidin-4- ylamine
Figure imgf000040_0002
The title compound, MS: m/e = 396.8 (M+), was prepared from 2-chlor-4-fluoro- benzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 46
5-Aminomethyl-2-benzo[&]thiophen-2-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine
Figure imgf000040_0003
The title compound, MS: m/e = 400.9 (M+H+), was prepared from benzo[&]thiophene-2- carboxamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 47
5-Aminomethyl-6-(2,4-dicUoro-phenyl)-2-(6-methoxy-naphthalen-2-yl)-pyrimidin-4- ylamine
Figure imgf000041_0001
The title compound, MS: m/e = 425.0 (M+H+), was prepared from 6-methoxy- naphthalene-2-carboxamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 48
5-Aminomethyl-2-phenyl-6-m-tolyl-pyrimidin-4-ylamine
Figure imgf000041_0002
The title compound, MS: m/e = 291.2 (M+H+), was prepared from 4-Amino-2-phenyl-6- m-tolyl-pyrimidine-5-carbonitrile in analogy to the process described in Example 11 as a solid.
Example 49
5-Aminomethyl-6-(4-chloro-phenyl)-2-phenyl-pyrimidin-4-ylamine
Figure imgf000041_0003
The title compound MS: m/e = 311.0 (M+H+), was prepared from 2-(4-chloro- benzylidene) -malononitrile in analogy to the process described in Example 11 as a solid.
Example 50
5-Aminomethyl-2-phenyl-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-ylamine
Figure imgf000042_0001
The title compound, MS: m/e = 344.0 (M+), was prepared from 2-(4-trifluoromethyl- benzylidene) -malononitrile in analogy to the process described in Example 11 as a solid.
Example 51
5-Aminomethyl-6-(2-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine
Figure imgf000042_0002
The title compound, MS: m/e = 306.8 (M+), was prepared from 2-(2-methoxy- benzylidene) -malononitrile in analogy to the process described in Example 11 as a solid.
Example 52
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-o-tolyl-pyrimidin-4-ylamine
Figure imgf000042_0003
The title compound, MS: m/e = 358.9 (M+H+), was prepared from 2-methyl-benzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid. Example 53
5-Aminomethyl-2-(3,5-bis-trifluoromethyl-phenyl)-6-(2,4-dichloro-phenyl)-pyrimidin-
4-ylamine
Figure imgf000043_0001
The title compound, MS: m/e = 481.2 (M+H+), was prepared from 3,5-bis- trifluoromethyl-benzamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 54
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-fluoro-phenoxymethyl)-pyrimidin-4- ylamine
Figure imgf000043_0002
The title compound, MS: m/e = 392.8 (M+H+), was prepared from 2-(4-fluoro-phenoxy)- acetamidine and 2- (2,4-dichloro-benzylidene) -malononitrile in analogy to the process described in Example 11 as a solid. Example 55
5-Aminomethyl-6-(2-chloro-phenyl)-2-phenyl-pyrimidin-4-ylamine
Figure imgf000044_0001
The title compound, MS: m/e = 311.0 (M+), was prepared from 2-(2-chloro-benzylidene)- malononitrile in analogy to the process described in Example 11 as a solid.
Example 56
5-Aminomethyl-6-(2-bromo-phenyl)-2-phenyl-pyrimidin-4-ylamine
Figure imgf000044_0002
The title compound, MS: m/e = 354.8 (M+), was prepared from 2-(2-bromo-benzylidene)- malononitrile in analogy to the process described in Example 11 as a solid.
Example 57
5-Aminomethyl-2-dibenzofuran-2-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine
Figure imgf000044_0003
The title compound, MS: m/e = 434.9 (M+), was prepared from dibenzofuran-2- carboxamidine and 2-(2,4-dichloro-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid. Example 58
5-Aminomethyl-6-(2,4-bis-trifluoromethyl-phenyl)-2-phenyl-pyrimidin-4-ylamine
Figure imgf000045_0001
The title compound, MS: m/e = 413.0 (M+H+), was prepared from 2-(2,4-bis- trifluoromethyl-benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 59
5-Aminomethyl-6-(2-fluoro-4-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine
Figure imgf000045_0002
The title compound, MS: m/e = 324.8 (M+), was prepared from 2-(2-fluoro-4-methoxy- benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid.
Example 60
5-Aminomethyl-6-(2,4-dimethoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine
Figure imgf000045_0003
The title compound, MS: m/e = 336.8 (M+), was prepared from 2-(2,4-dimethoxy- benzylidene) -malononitrile in analogy to the process described in Example 11 as a solid. Example 61
5-Aminomethyl-2-(lH-indol-2-yl)-6-phenyl-pyrimidin-4-ylamine
Figure imgf000046_0001
The title compound, MS: m/e = 315.8 (M+H+), was prepared from lH-indole-2- carboxamidine and 2-benzylidene-malononitrile in analogy to the process described in Example 11 as a solid.
Example 62
5-Aminomethyl-6-benzo [1,3] dioxol-5-yl-2-cyclopropyl-pyrimidin-4-ylamine
Figure imgf000046_0002
The title compound, MS: m/e = 284.7 (M+H+), was prepared from cyclopropylcarboxamidine and 2-benzo[l,3]dioxol-5-ylmethylene-malononitrile in analogy to the process described in Example 11 as a solid.
Example 63
5-Aminomethyl-6-(2-fluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine
Figure imgf000046_0003
The title compound, MS: m/e = 294.9 (M+H+), was prepared from 2-(2-fluoro- benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid. Example 64
5-Aminomethyl-2-phenyl-6-(2-trifluoromethyl-phenyl)-pyrimidin-4-ylamine
Figure imgf000047_0001
The title compound, MS: m/e = 345.1 (M+H+), was prepared from 2-(2-trifluoromethyl- benzylidene) -malononitrile in analogy to the process described in Example 11 as a solid.
Example 65
5-Aminomethyl-2-benzofαran-2-yl-6-phenyl-pyrimidin-4-ylamine
Figure imgf000047_0002
The title compound, MS: m/e = 316.7 (M+H+), was prepared from benzofuran-2- carboxamidine and 2-benzylidene-malononitrile in analogy to the process described in Example 11 as a solid.
Example 66
5-Aminomethyl-6-(4-fluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine
Figure imgf000047_0003
The title compound, MS: m/e = 294.8 (M+H+), was prepared from 2~(4-fiuoro- benzylidene) -malononitrile in analogy to the process described in Example 11 as a solid. Example 67
5-Aminomethyl-2-(3,4-dimethoxy-phenyl)-6-phenyl-pyrimidin-4-ylamine
Figure imgf000048_0001
The title compound, MS: m/e = 336.8 (M+H+), was prepared from 3,4- dimethoxyb enzamidine and 2-benzylidene-malononitrile in analogy to the process described in Example 11 as a solid.
Example 68
5-Aminomethyl-6-phenyl-2-pyridin-4-yl-pyrimidin-4-ylamine
Figure imgf000048_0002
The title compound, MS: m/e = 278.0 (M+H+), was prepared from isonicotinamidine and 2-benzylidene-malononitrile in analogy to the process described in Example 11 as a solid.
Example 69
5-Aminomethyl-6-(3-chloro-phenyl)-2-phenyl-pyrimidin-4-ylamine
Figure imgf000048_0003
The title compound, MS: m/e = 31.0 (M+H+), was prepared from 2-(3-chloro- benzylidene)-malononitrile in analogy to the process described in Example 11 as a solid. Example 70
5-Aminomethyl-6-phenyl-2-thiophen-2-yl-pyrimidin-4-ylamine
Figure imgf000049_0001
The title compound, MS: m/e = 282.8 (M+H+), was prepared from thiophene-2- carboxamidine and 2-benzylidene-malononitrile in analogy to the process described in Example 11 as a solid.
Example 71
5-Aminomethyl-6-(3-fluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine
Figure imgf000049_0002
The title compound, MS: m/e = 294.8 (M+H+), was prepared from 2-(3-fluoro- benzylidene) -malononitrile in analogy to the process described in Example 11 as a solid.
Example 72
5-Aminomethyl-2,6-diphenyl-pyrimidin-4-ylamine
Figure imgf000049_0003
The title compound, MS: m/e = 276.9 (M+H+), was prepared from 2-benzylidene- malononitrile in analogy to the process described in Example 11 as a solid. Example 73
5-Aminomethyl-6-(4-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine
Figure imgf000050_0001
The title compound, MS: m/e = 306.9 (M+H+), was prepared from 2-(4-metoxy- benzylidene) -malononitrile in analogy to the process described in Example 11 as a solid.
Example 74
5-Aminomethyl-2-phenyl-6-thiophen-3-yl-pyrimidin-4-ylamine
Figure imgf000050_0002
The title compound, MS: m/e = 283.0 (M+H+), was prepared from 2-thiophen-3- ylmethylene-malononitrile in analogy to the process described in Example 11 as a solid.
Example 75
5-Aminomethyl-6-(3-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine
Figure imgf000050_0003
The title compound, MS: m/e = 307.2 (M+H+), was prepared from 4-Amino-6-(3- methoxy-phenyl)-2-phenyl-pyrimidine-5-carbonitrile in analogy to the process described in Example 11 as a solid. Example 76
(Procedure 6 in Reaction Scheme I)
6-(2,4-Dichloro-phenyl)-5-methylaminomethyl-2-phenyl-pyrimidin-4-ylamine
Figure imgf000051_0001
Under an atmosphere of argon, 9-BBN (0.348ml of a 0.5molar solution in hexane, 0.174mmol) was added to a solution of 4-amino-6-(2,4-dichloro-phenyl)-2-phenyl- pyrimidine-5-carbonitrile (60mg, 0.174mmol) in THF (1ml) and stirred for 2.5h at r.t. Potassium- tert-butylate (20mg, 0.174mmol) was added, followed by a drop of Methyl iodide after lOmin. The mixture was stirred overnight, then ethanolamine (llmg, 0.174mmol) was added and the mixture was heated to 50°C for 3h. After cooling, the mixture was filtered, and the filtrate was evaporated. Purification ofthe re-dissolved (DMF, 1ml) residue by automated, preparative HPLC (YMC CombiPrep C18 column 50x20mm, solvent gradient 5-95% CH3CN in 0.1% TFA(aq) over 6.0min, λ = 230nm, flow rate 40ml/min) gave the title compound, MS: m/e = 358.9 (M+H+), (12mg, 19%) as a foam.
Example 77
Synthesis of 2-Amino-nicotinonitriles (Procedure 7 in Reaction Scheme II)
2-Amino-4-(2,4-dichloro-phenyl)-6-phenyl-nicotinonitrile
A mixture of 2-(2,4-dichloro-benzylidene)-malononitrile (1.125g, 5mmol), acetophenone (601mg, 5mmol), ammonium acetate (578mg, 7.5mmol), and toluene (5ml) was stirred for 3h at reflux. Upon cooling to room temperature, the mixture was taken up in ethyl acetate and extracted with satd. NaHCO3, water, and satd. NaCl, and dried over Na SO4. The solvent was then evaporated and the title compound (600mg, 35%), MS: m/e = 339.5 (M+H+), was isolated from the residue by column chromatography (silica gel, hexanes, ethyl acetate). 1H-NMR (300MHz, CDC13, 25°C): δ(ppm) = 5.38 (2H, bs), 7.13 (IH, s), 7.30-7.58 (6H, m), 7.95-8.02 (2H, m).
The following 2-amino-nicotinonitrile was prepared in analogy to the procedure described above:
2-Amino-4-(2,4-dichloro-phenyl)-5-methyl-6-phenyl-nicotinonitrile, MS: m/e = 353.9 (M+H+), was prepared from propiophenone as a solid (425mg, 24%).
Example 78
Synthesis of 3-Aminomethyl-pyridin-2-ylamines (Procedure 8 in Reaction Scheme II)
3-Aminomethyl-4-(2,4-dichloro-phenyl)-6-phenyl-pyridin-2-ylamine
Figure imgf000052_0001
Under an atmosphere of argon, a solution of 2-amino-4-(2,4-dichloro-phenyl)-6-phenyl- nicotinonitrile (580mg, 1.71mmol) in THF (2ml) is added slowly to a suspension of L-AIH4 (324mg, 8.52mmol) in THF (2ml). After stirring for 2h at room temperature, the reaction mixture is cooled to -20°C and water (0.4ml) is added. After 15min, ethyl acetate is added and the mixture is filtered through Decalite. The organic phase is then separated, washed with water, and dried over sodium sulfate. Purification by flash chromatography (silica gel, methanol, dichloromethane) affords the title compound, MS: m/e = 343.8 (M+H+), as a light yellow solid (36mg, 6%).
1H-NMR (300MHz, CDC13, 25°C): δ(ppm) = 3.40 (IH, d, J = 10Hz), 3.59 (IH, d, J = 10Hz), 6.49 (2H, bs), 6.90 (IH, s), 7.30-7.55 (5H, m), 7.57 (IH, s), 7.90-8.10 (2H, m) Example 79
3-Aminomethyl-4-(2,4-dichloro-phenyl)-5-methyl-6-phenyl-pyridin-2-ylamine
Figure imgf000053_0001
The title compound, MS: m/e = 357.9 (M+), was prepared from 2-amino-4-(2,4-dichloro- phenyl)-5-methyl-6-phenyl-nicotinonitrile in analogy to the process described in Example 78 as a solid (22mg, 9%).
Example 80
High-Throughput Reduction of carbonitriles to aminomethyl compounds (Procedure 9 in Reaction Schemes I and II)
[5-Aminomethyl-6-(4-chloro-phenyl)-2-pyridin-3-yl-pyrimidin-4-yl]-methyl-amine
Figure imgf000053_0002
High-Throughput Reduction of carbonitriles to aminomethyl compounds
4-(4-Chlorophenyl)-6-(dimethylamino)-2-(3-pyridinyl)-5-pyrimidinecarbonitrile (Bionet) (50mg, 0.155mmol) was dissolved in THF (1ml) and added, under an atmosphere of argon, to a cooled (0°C) suspension of lOOmg of Lithium aluminim hydride in 1ml THF in a reaction vial. The raction mixture was shaken first for 2h at r.t. and subsequently for 4h at 40°C. Upon cooling, water was added carefully and the mixture was filtered. The filtrate was evaporated in a vacuum zentrifuge (45°C). Purification ofthe re-dissolved (DMF, 1ml) residue by automated, preparative HPLC (YMC CombiPrep C18 column
50x20mm, solvent gradient 5-95% CH3CN in 0.1% TFA(aq) over 6.0min, λ = 230nm, flow rate 40ml/min) gave 17mg (34%) ofthe title compound, MS: m/e = 326.0 (M+H+), as a solid. Example 81
5-Aminomethyl-6-benzo[l,3]dioxol-5-yl-2-(4-methoxy-phenyl)-pyrimidin-4-ylamine
Figure imgf000054_0001
The title compound, MS: m/e = 351.0 (M+H+), was prepared in analogy to the process described in Example 80 from 4-amino-6-benzo[l,3]dioxol-5-yl-2-(4-mefhoxy-phenyl)- pyrimidine-5-carbonitrile.
Example 82
5-Aminomethyl-6-benzo[l,3]dioxol-5-yl-2-phenyl-pyrimidin-4-ylamine
Figure imgf000054_0002
The title compound, MS: m/e = 321.0 (M+H+), was prepared in analogy to the process described in Example 80 from 4-amino-6-benzo[l,3]dioxol-5-yl-2-phenyl-pyrimidine-5- carbonitrile.
Example 83
[5-Aminomethyl-6-(4-chloro-phenyl)-2-pyridin-3-yl-pyrimidin-4-yl]-isopropyl-amine
Figure imgf000054_0003
The title compound, MS: m/e = 354.1 (M+H+), was prepared in analogy to the process described in Example 80 from 4-(4-chlorophenyl)-6-(isopropylamino)-2-(3-pyridinyl)-5- pyrimidinecarbonitrile. Example 84
(5-Aminomethyl-2,6-diphenyl-pyrimidin-4-yl)-methyl-amine
Figure imgf000055_0001
The title compound, MS: m/e = 290.9 (M+H+), was prepared in analogy to the process described in Example 80 from 4-(methylamino)-2,6-diphenyl-5-pyrimidinecarbonitrile (Bionet).
Example 85
3-Aminomethyl-4-(4-chloro-phenyl)-5-methyl-6-phenyl-pyridin-2-ylamine
Figure imgf000055_0002
The title compound, MS: m/e = 323.9 (M+H+), was prepared in analogy to the process described in Example 80 from 2-amino-4-(4-chlorophenyl)-5-methyl-6- phenylnicotinonitrile (Bionet).
Example 86
3-Aminomethyl-4-(4-chloro-phenyl)-6-phenyl-pyridin-2-ylamine
Figure imgf000055_0003
The title compound, MS: m/e = 310.3 (M+H+), was prepared in analogy to the process described in Example 80 from 2-amino-4-(4-chlorophenyl)-6-phenylnicotinonitrile (Bionet). Example 87
3-Aminomethyl-4,6-bis-(4-fluoro-phenyl)-pyridin-2-ylamine
Figure imgf000056_0001
The title compound, MS: m/e = 311.9 (M+H+), was prepared in analogy to the process described in Example 80 from 2-amino-4,6-bis(4-fiuorophenyl)nicotinonitrile (Bionet).
Example 88
(Procedure 10 in Reaction Scheme II)
3-Aminomethyl-4-benzo [ 1,3] dioxol-5-yl-6-phenyl-pyridin-2-ylamine
Figure imgf000056_0002
2-Benzo[l,3]dioxol-5-ylmethylene-malononitrile (79mg, 0.4mmol), benzophenone (48mg, 0.4mmol), ammonium acetate (78mg, 1.2mmol), and toluene (4ml) were placed in a reaction vial and shaken overnight at 118°C. Upon cooling and filtration, the solution was evaporated in a vacuum zentrifuge (45°C) and the residue was purified by automated, preparative HPLC (YMC CombiPrep C18 column 50x20mm, solvent gradient 5-95% CH3CN in 0.1% TFA(aq) over 6.0min, λ = 230nm, flow rate 40ml/min). The obtained solid (28mg) was dissolved in THF (1ml) and added, under an atmosphere of argon, to a cooled (0°C) suspension of lOOmg of lithium aluminim hydride in 1ml THF in a reaction vial. The raction mixture was shaken first for 2h at r.t. and subsequently for 4h at 40°C. Upon cooling, water was added carefully and the mixture was filtered. The filtrate was evaporated in a vacuum zentrifuge (45°C). Purification ofthe re-dissolved (DMF, 1ml) residue by automated, preparative HPLC (YMC CombiPrep C18 column 50x20mm, solvent gradient 5-95% CH3CN in 0.1% TFA(aq) over 6.0min, λ = 230nm, flow rate 40ml/min) gave llmg (7%) ofthe title compound, MS: m/e = 320.1 (M+H+), as a solid. Galenical Examples
Example A
Film coated tablets containing the following ingredients can be manufactured in a conventional manner:
Ingredients Per tablet
Kernel:
Compound of formula (I) 10.0 mg 200.0 mg
Microcrystalline cellulose 23.5 mg 43.5 mg
Lactose hydrous 60.0 mg 70.0 mg
Povidone K30 12.5 mg 15.0 mg
Sodium starch glycolate 12.5 mg 17.0 mg
Magnesium stearate 1.5 mg 4.5 mg
(Kernel Weight) 120.0 mg 350.0 mg
Film Coat:
Hydroxypropyl methyl cellulose 3.5 mg 7.0 mg
Polyethylene glycol 6000 0.8 mg 1.6 mg
Talc 1.3 mg 2.6 mg
Iron oxyde (yellow) 0.8 mg 1.6 mg
Titan dioxide 0.8 mg 1.6 mg
The active ingredient is sieved and mixed with microcrystalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidon in water. The granulate is mixed with sodium starch glycolate and magesium stearate and compressed to yield kernels of 120 or 350 mg respectively. The kernels are lacquered with an aq. solution / suspension ofthe above mentioned film coat. Example B
Capsules containing the following ingredients can be manufactured in a conventional manner:
Ingredients Per capsule
Compound of formula (I) 25.0 mg
Lactose 150.0 mg
Maize starch 20.0 mg
Talc 5.0 mg
The components are sieved and mixed and filled into capsules of size 2.
Example C
Injection solutions can have the following composition:
Compound of formula (I) 3.0 mg
Polyethylene Glycol 400 150.0 mg
Acetic Acid q.s. ad pH 5.0
Water for injection solutions ad 1.0 ml The active ingredient is dissolved in a mixture of polyethylene glycol 400 and water for injection (part). The pH is adjusted to 5.0 by acetic acid. The volume is adjusted to 1.0 ml by addition ofthe residual amount of water. The solution is filtered, filled into vials using an appropriate overage and sterilized.
Example D
Soft gelatin capsules containing the following ingredients can be manufactured in a conventional manner:
Capsule contents
Compound of formula (I) 5.0 mg
Yellow wax 8.0 mg
Hydrogenated Soya bean oil 8.0 mg
Partially hydrogenated plant oils 34.0 mg
Soya bean oil 110.0 mg
Weight of capsule contents 165.0 mg Gelatin capsule
Gelatin 75.0 mg
Glycerol 85 % 32.0 mg Karion 83 8.0 mg (dry matter)
Titan dioxide 0.4 mg
Iron oxide yellow 1.1 mg
The active ingredient is dissolved in a warm melting ofthe other ingredients and the mixture is filled into soft gelatin capsules of appropriate size. The filled soft gelatin capsules are treated according to the usual procedures.
Example E
Sachets containing the following ingredients can be manufactured in a conventional manner:
Compound of formula (I) 50.0 mg
Lactose, fine powder 1015.0 mg
Microcristalline cellulose (AVICEL PH 102) 1400.0 mg
Sodium carboxymethyl cellulose 14.0 mg
Polyvinylpyrrolidon K 30 10.0 mg
Magnesium stearate 10.0 mg
Flavoring additives 1.0 mg
The active ingredient is mixed with lactose, microcrystalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidon in water. The granulate is mixed with magnesium stearate and the flavouring additives and filled into sachets.

Claims

Claims
1. Compounds of formula (I)
Figure imgf000060_0001
wherein
X is N or C-R5;
R1 and R2 are independently hydrogen or lower alkyl;
R3 is heterocyclyl; heterocyclyl mono-, di-, or tri-substituted, independently, by lower alkyl, lower alkoxy, perfluoro-lower alkyl, amino or halogen; aryl; or aryl mono-, di-, or tri-substituted, independently, by halogen, lower alkyl, lower alkoxy, amino or perfluoro-lower alkyl;
R4 is lower alkyl; lower alkoxy; lower alkylthio; heterocyclyl; heterocyclyl mono-, di-, or tri-substituted, independently, by lower alkyl, lower alkoxy, perfluoro-lower alkyl, amino or halogen; aryl; aryl mono-, di-, or tri-substituted, independently, by lower alkyl, lower alkoxy, halogen, amino, or perfluoro-lower alkyl; aryloxy lower alkyl or cycloalkyi;
R5 is hydrogen or lower alkyl; and pharmaceutically acceptable salts thereof.
2. Compounds according to any claim 1, wherein R1 is hydrogen.
3. Compounds according to any of claims 1 to 2, wherein R2 is hydrogen.
4. Compounds according to any of claims 1 to 3, wherein X is N.
5. Compounds according to any of claims 1 to 4, wherein R3 is heterocyclyl selected from pyridyl, pyrimidinyl, furyl, thienyl, indolyl, benzo[l,3]dioxolyl, benzofuranyl, benzothiophenyl, dibenzofuranyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazol l, tetrazolyl, oxatriazolyl, thiatriazolyl, pyridazyl, pyrimidinyl, pyrazinyl, pyrrolidinyl, azepanyl, and morpholino, which heterocyclyl is optionally mono-, di- or tri-substituted, independently, by halogen, amino, perfluoro-lower alkyl, lower alkyl or lower alkoxy.
6. Compounds according to claim5, wherein R3 is unsubstituted thienyl or unsubstituted benzo [ 1,3] dioxolyl.
7. Compounds according to any of claims 1 to 4, wherein R3 is phenyl, optionally ortho-, meta- or p ra-substituted, independently, by lower alkyl, lower alkoxy, halogen, amino or perfluoro-lower alkyl.
8. Compounds according to claim 7, wherein R3 is 2,4-dichloro-phenyl.
9. Compounds according to any of claims 1 to 8, wherein R4 is phenyl, optionally ortho-, meta- and/or pαr -substituted, independently, by halogen, amino, lower alkyl, perfluoro-lower alkyl or lower alkoxy.
10. Compounds according to any of claims 1 to 8, wherein R4 is lower alkoxy.
11. Compounds according to any of claims 1 to 8, wherein R4 is lower alkylthio.
12. Compounds according to any of claims 1 to 8, wherein R is a heterocyclic residue selected from pyridyl, thienyl, indolyl, benzo [1,3] dioxolyl, benzofuranyl, benzothiophenyl, dibenzofuranyl, pyrrolidinyl, azepanyl and morpholino, which heterocyclic residues ma be mono-, di- or tri-substituted, independently, by halogen, amino, perfluoro-lower alkyl, lower alkyl or lower alkoxy.
13. Compounds according to any of claims 1 to 12, wherein X is N, R1 and R2 are hydrogen, R3 is 2,4-dichloro-phenyl, and R4 is methoxy, methylthio, a heterocyclic residue selected from pyrrolidinyl and azepanyl, or a phenyl reside which may optionally be ortho-, meta- and/ or r -substituted, independently, by fluoro, methyl or methoxy.
14. Compounds according to any of claims 1 to 13, wherein X is N or C-R5, R1 is hydrogen or lower alkyl, R2 is hydrogen or lower alkyl, R3 is unsubstituted thienyl, unsubstituted benzo[l,3]dioxolyl, or phenyl which may be ortho-, meta- and/or para- substituted, independently, by lower alkyl, lower alkoxy, halogen or perfluoro-lower alkyl, R4 is lower alkyl, lower alkoxy, lower alkylthio, C3-6-cycloalkyl, heterocyclyl selected from pyridyl, thienyl, indolyl, benzo [1,3] dioxolyl, benzofuranyl, benzothiophenyl, dibenzofuranyl, pyrrolidinyl, azepanyl and morpholino, and which heterocyclyl residue may be mono- or di-substituted, independently, by lower alkyl or lower alkoxy, a naphthyl residue which may be mono-substituted by lower alkoxy, a phenyl residue which may be ortho-, meta- and/or r -substituted, independently, by halogen, amino, lower alkyl, perfluoro-lower alkyl or lower alkoxy, or phenoxy lower alkyl, wherein the phenyl moiety is substituted by halogen, and R5 is hydrogen or lower alkyl.
15. Compounds according to any of claims 1 to 14, selected from the group consisting of:
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-2-phenyl-6-p-tolyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-methoxy-phenyl)-pyrimidin-4- ylamine, 5-Aminomethyl-2-phenyl-6-o-tolyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-difluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-m-tolyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,4,5-trimethoxy-phenyl)- pyrimidin-4-ylamine, 5-Aminomethyl-6-(2,4-dimethyl-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,5-dimethoxy-phenyl)-pyrimidin- 4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-fluoro-phenyl)-pyrimidin-4- ylamine, 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-fluoro-phenyl)-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-methoxy-l-methyl-lH-indol-6- yl)-pyrimidin-4-ylamine,
5-Aminomethyl-2-benzofuran-2-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(lH-indol-2-yl)-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-m-tolyl-pyrimidin-4-ylamine,
2-(4-Amino-3-methoxy-phenyl)-5-aminomethyl-6-(2,4-dichloro-phenyl)- pyrimidin-4-ylamine, 5-Aminomethyl-2-azepan-l-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,4-difluoro-phenyl)-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-dichloro-ρhenyl)-2-pyrrolidin-l-yl-pyrimidin-4-ylamine, 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-methylsulfanyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,4-dimethoxy-phenyl)-pyrimidin- 4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-thiophen-2-yl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(2-fluoro-phenyl)-pyrimidin-4- ylamine,
5-Aminomethyl-2-(4-chloro-phenyl)-6-(2,4-dichloro-phenyl)-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-methoxy-pyrimidin-4-ylamine,
5-Aminomethyl-2-cyclopropyl-6-phenyl-pyrimidin-4-ylamine5-Aminomethyl-6- (2,4-dichloro-phenyl)-2-p-tolyl-pyrimidin-4-yiamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-methoxy-phenyl)-pyrimidin-4- ylamine,
5-Aminomethyl-2-benzo[l,3]dioxol-5-yl-6-(2,4-dichloro-phenyi)-pyrimidin-4- ylamine, 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-trifluoromethyl-phenyl)- pyrimidin-4-ylamine,
5-Aminomefhyl-6-(2,4-dichloro-phenyl)-2-morpholin-4-yl-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(4-trifluoromethyl-phenyl)- pyrimidin-4-ylamine,
5-Aminomethyl-2-(3-chloro-phenyl)-6-(2,4-dichloro-phenyl)-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-methyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-naphfhalen-2-yl-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-naphthalen-l-yl-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3-methoxy-phenyl)-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(3,5-difluoro-phenyl)-pyrimidin-4- ylamine,
5- Aminomethyl-6- (2,4-dichloro-phenyl) -2- (2-methoxy-phenyl) -pyrimidin-4- ylamine,
5-Aminomethyl-6-(4-efhyl-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-isopropyl-pyrimidin-4-ylamine, 5-Aminomethyl-2-(2-chloro-4-fluoro-phenyl)-6-(2,4-dichloro-phenyl)- pyrimidin-4-ylamine,
5-Aminomethyl-2-benzo[b]thiophen-2-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(6-methoxy-naphthalen-2-yl)- pyrimidin-4-ylamine,
5-Aminomethyl-2-phenyl-6-m-tolyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(4-chloro-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-2-phenyl-6-(4-trifluoromethyl-phenyl)-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine, 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-o-tolyl-pyrimidin-4-ylamine,
5-Aminomethyl-2-(3,5-bis-trifluoromethyl-phenyl)-6-(2,4-dichloro-phenyl)- pyrimidin-4-ylamine,
5-Aminomefhyl-6-(2,4-dichloro-phenyl)-2-(4-fluoro-phenoxymethyl)- pyrimidin-4-ylamine, 5-Aminomethyl-6-(2-chloro-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(2-bromo-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-2-dibenzofuran-2-yl-6-(2,4-dichloro-phenyl)-pyrimidin-4- ylamine,
5-Aminomethyl-6-(2,4-bis-trifluoromethyl-phenyl)-2-phenyl-pyrimidin-4- ylamine, 5-Aminomethyl-6-(2-fluoro-4-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine, 5-Aminomethyl-6-(2,4-dimethoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine, 5-Aminomethyl-2- ( lH-indol-2-yl)-6-phenyl-pyrimidin-4-ylamine, 5-Aminomethyl-6-benzo[l,3]dioxol-5-yl-2-cyclopropyl-pyrimidin-4-ylamine, 5-Aminomethyl-6-(2-fluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-2-phenyl-6-(2-trifluoromethyl-phenyl)-pyrimidin-4-ylamine, 5-Aminomethyl-2-benzofuran-2-yl-6-phenyl-pyrimidin-4-ylamine, 5-Aminomethyl-6-(4-fluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine, 5-Aminomethyl-2-(3,4-dimethoxy-phenyl)-6-phenyl-pyrimidin-4-ylamine, 5-Aminomethyl-6-phenyl-2-pyridin-4-yl-pyrimidin-4-ylamine,
5-Aminomethyl-6-(3-chloro-phenyl)-2-phenyl-pyrimidin-4-ylamine, 5-Aminomethyl-6-phenyl-2-thiophen-2-yl-pyrimidin-4-ylamine, 5-Aminomethyl-6-(3-fluoro-phenyl)-2-phenyl-pyrimidin-4-ylamine, 5-Aminomethyl-2,6-diphenyl-pyrimidin-4-ylamine, 5-Aminomethyl-6-(4-mefhoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine,
5-Aminomethyl-2-phenyl-6-thiophen-3-yl-pyrimidin-4-ylamine, 5-Aminomethyl-6-(3-methoxy-phenyl)-2-phenyl-pyrimidin-4-ylamine, 6-(2,4-Dichloro-phenyl)-5-methylaminomethyl-2-phenyl-pyrimidin-4-ylamine, 3-Aminomethyl-4-(2,4-dichloro-phenyl)-6-phenyl-pyridin-2-ylamine, 3-Aminomethyl-4-(2,4-dichloro-phenyl)-5-methyl-6-phenyl-pyridin-2-ylamine,
[5-Aminomethyl-6-(4-chloro-phenyl)-2-pyridin-3-yl-pyrimidin-4-yl]-methyl- amine,
5-Aminomethyl-6-benzo[l,3]dioxol-5-yl-2-(4-methoxy-phenyl)-pyrimidin-4- ylamine, 5-Aminomethyl-6-benzo [ 1,3] dioxol-5-yl-2-phenyl-pyrimidin-4-ylamine,
[5-Aminomethyl-6-(4-chloro-phenyl)-2-pyridin-3-yl-pyrimidin-4-yl] -isopropyl- amine,
(5-Aminomethyl-2,6-diphenyl-pyrimidin-4-yl)-methyl-amine,
3-Aminomethyl-4-(4-chloro-phenyl)-5-methyl-6-phenyl-pyridin-2-ylamine, 3-Aminomethyl-4-(4-chloro-phenyl)-6-phenyl-pyridin-2-ylamine, 3-Aminomethyl-4,6-bis-(4-fluoro-phenyl)-pyridin-2-ylamine, and 3-Aminomethyl-4-benzo [1,3] dioxol-5-yl-6-phenyl-pyridin-2-ylamine,
and pharmaceutically acceptable salts thereof.
16. A process for the manufacture of compounds of formula (I) as defined in any of claims 1 to 15, which process comprises:
(a) reduction of a nitrile of formulae
Figure imgf000066_0001
IVa or I wherein R1, R3 and R4 are as defined in any of claims 1 to 15; to an amine of formula
Figure imgf000066_0002
la wherein R1, R3 and R4 are as defined in any of claims 1 to 15. (b) reduction of a nitrile of formulae
wherein
Figure imgf000066_0003
in any of claims 1 to 15; to an amine of formula lc
Figure imgf000066_0004
lc wherein R1, R3, R4, and R5 are as defined in any of claims 1 to 15; or (c) alkylating an amine of formula la
Figure imgf000067_0001
la wherein R1, R3 and R4 are as defined in any of claims 1 to 15; to a compound of formula lb
Figure imgf000067_0002
lb wherein R1, R2, R3 and R4 are as defined in any of claims 1 to 15.
(d) alkylating an amine of formula lc
Figure imgf000067_0003
wherein R1, R5, R4 and R5 are as defined in any of claims 1 to 15; to a compound of formula Id
Figure imgf000067_0004
Id wherein R1, R2, R3, R4 and R5 are as defined in any of claims 1 to 15.
17. Compounds according to any of claims 1 to 15 when manufactured by a process according to claim 16.
18. Pharmaceutical compositions comprising a compound according to any of claims 1 to 15 and a pharmaceutically acceptable carrier and/or adjuvant.
19. Compounds according to any of claims 1 to 15 for use as therapeutic active substances.
20. Compounds according to any of claims 1 to 15 for use as therapeutic active substances for the treatment and/or prophylaxis of diseases which are associated with DPP IN
21. A method for the treatment and/or prophylaxis of diseases which are associated with DPP IV such as diabetes, non-insulin dependent diabetes mellitus, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn, hypertension, diseases wherein a diuretic agent has a beneficial effect, obesity, and/or metabolic syndrome, which method comprises administering a compound according to any of claims 1 to 15 to a human being or animal.
22. The use of compounds according to any of claims 1 to 15 for the treatment and/or prophylaxis of diseases which are associated with DPP IV.
23. The use of compounds according to any of claims 1 to 15 for the treatment and/or prophylaxis of diabetes, non-insulin-dependent diabetes mellitus, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn, hypertension, diseases wherein a diuretic agent has a beneficial effect, obesity, and/or metabolic syndrome.
24. The use of compounds according to any of claims 1 to 15 for the preparation of medicaments for the treatment and/or prophylaxis of diseases which are associated with DPP IV.
25. The use of compounds according to any of claims 1 to 15 for the preparation of medicaments for the treatment and/or prophylaxis of diabetes, non-insulin-dependent diabetes mellitus, impaired glucose tolerance, Bowl disease, Colitis Ulcerosa, Morbus Crohn, hypertension, diseases wherein a diuretic agent has a beneficial effect, obesity, and/or metabolic syndrome.
26. The novel compounds, processes and methods as well as the use of such compounds substantially as described hereinbefore.
PCT/EP2003/001107 2002-02-13 2003-02-05 Novel pyridin- and pyrimidin-derivatives WO2003068757A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP03704536A EP1476435B1 (en) 2002-02-13 2003-02-05 Novel pyridin- and pyrimidin-derivatives
JP2003567888A JP4359146B2 (en) 2002-02-13 2003-02-05 Novel pyridine- and pyrimidine-derivatives
BR0307665-2A BR0307665A (en) 2002-02-13 2003-02-05 Compounds, process for their manufacture, pharmaceutical compositions comprising them, method for treating and / or prophylaxis of diseases associated with dpp iv and use of the compounds
AT03704536T ATE472536T1 (en) 2002-02-13 2003-02-05 PYRIDINE AND PYRIMIDINE DERIVATIVES
AU2003206833A AU2003206833B2 (en) 2002-02-13 2003-02-05 Novel pyridin- and pyrimidin-derivatives
CA002474578A CA2474578C (en) 2002-02-13 2003-02-05 Novel pyridin- and pyrimidin-derivatives
MXPA04007744A MXPA04007744A (en) 2002-02-13 2003-02-05 Novel pyridin- and pyrimidin-derivatives.
DE60333166T DE60333166D1 (en) 2002-02-13 2003-02-05 PYRIDINE AND PYRIMIDINE DERIVATIVES
KR1020047012449A KR100608414B1 (en) 2002-02-13 2003-02-05 Novel pyridin- and pyrimidin-derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02003114.2 2002-02-13
EP02003114 2002-02-13

Publications (2)

Publication Number Publication Date
WO2003068757A1 WO2003068757A1 (en) 2003-08-21
WO2003068757A9 true WO2003068757A9 (en) 2004-10-07

Family

ID=27675614

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/001107 WO2003068757A1 (en) 2002-02-13 2003-02-05 Novel pyridin- and pyrimidin-derivatives

Country Status (21)

Country Link
US (2) US6867205B2 (en)
EP (1) EP1476435B1 (en)
JP (1) JP4359146B2 (en)
KR (1) KR100608414B1 (en)
CN (1) CN1324015C (en)
AR (1) AR038484A1 (en)
AT (1) ATE472536T1 (en)
AU (1) AU2003206833B2 (en)
BR (1) BR0307665A (en)
CA (1) CA2474578C (en)
DE (1) DE60333166D1 (en)
ES (1) ES2345096T3 (en)
GT (1) GT200300037A (en)
MX (1) MXPA04007744A (en)
PA (1) PA8566101A1 (en)
PE (1) PE20030940A1 (en)
PL (1) PL371678A1 (en)
RU (1) RU2293731C2 (en)
TW (1) TW200303199A (en)
UY (1) UY27665A1 (en)
WO (1) WO2003068757A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1542978B1 (en) * 2002-07-22 2011-04-13 Orchid Research Laboratories Limited Novel bio-active molecules
CN1894234A (en) * 2003-03-25 2007-01-10 武田药品工业株式会社 Dipeptidyl peptidase inhibitors
WO2004098591A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
EP1625122A1 (en) 2003-05-14 2006-02-15 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
MXPA06001601A (en) 2003-08-13 2006-08-25 Takeda Pharmaceutical 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors.
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005026148A1 (en) * 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20050065144A1 (en) * 2003-09-08 2005-03-24 Syrrx, Inc. Dipeptidyl peptidase inhibitors
GB0323137D0 (en) 2003-10-03 2003-11-05 Chang Lisa C W 2,4,6- Trisubstituted pyrimidines and their different uses
DE10348022A1 (en) * 2003-10-15 2005-05-25 Imtm Gmbh New dipeptidyl peptidase IV inhibitors for the functional influence of different cells and for the treatment of immunological, inflammatory, neuronal and other diseases
BRPI0415678A (en) * 2003-10-23 2006-12-19 Pharmacia Corp pyrimidine compounds for treating inflammation
PE20050444A1 (en) * 2003-10-31 2005-08-09 Takeda Pharmaceutical PYRIDINE COMPOUNDS AS PEPTIDASE INHIBITORS
EP1680120A2 (en) 2003-11-03 2006-07-19 Probiodrug AG Combinations useful for the treatment of neuronal disorders
KR20140089408A (en) 2003-11-17 2014-07-14 노파르티스 아게 Use of dipeptidyl peptidase iv inhibitors
PT1715893E (en) 2004-01-20 2009-10-20 Novartis Pharma Ag Direct compression formulation and process
CN1918131B (en) 2004-02-05 2011-05-04 前体生物药物股份公司 Novel inhibitors of glutaminyl cyclase
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102079743B (en) 2004-03-15 2020-08-25 武田药品工业株式会社 Dipeptidyl peptidase inhibitors
US7280223B2 (en) * 2004-04-22 2007-10-09 Zygo Corporation Interferometry systems and methods of using interferometry systems
TW200608976A (en) 2004-05-08 2006-03-16 Neurogen Corp 4,5-disubstituted-2-aryl pyrimidines
WO2005118555A1 (en) 2004-06-04 2005-12-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
DOP2006000008A (en) 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
ZA200708144B (en) * 2005-02-25 2008-11-26 Takeda Pharmaceutical Pyridyl acetic acid compounds
WO2007015805A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company 1-amino linked compounds
WO2007015767A1 (en) * 2005-07-20 2007-02-08 Eli Lilly And Company Pyridine derivatives as dipeptedyl peptidase inhibitors
MX2008001799A (en) * 2005-08-11 2008-04-16 Hoffmann La Roche Pharmaceutical composition comprising a dpp-iv inhibitor.
WO2007033350A1 (en) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
PL1931350T5 (en) * 2005-09-14 2021-11-15 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
EP1924567B1 (en) 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
JP2009531456A (en) * 2006-03-28 2009-09-03 武田薬品工業株式会社 Preparation of (R) -3-aminopiperidine dihydrochloride
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2004643A1 (en) 2006-03-31 2008-12-24 Novartis AG Organic compounds
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
AR060406A1 (en) 2006-04-11 2008-06-11 Arena Pharm Inc METHODS FOR USING THE GPR119 RECEIVER IN THE IDENTIFICATION OF USEFUL COMPOUNDS TO INCREASE THE OSEA MASS IN AN INDIVIDUAL
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
CA2663279C (en) * 2006-09-13 2016-05-17 Takeda Pharmaceutical Company Limited Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer, autoimmune disorders and hiv infection
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
SI2091948T1 (en) 2006-11-30 2012-07-31 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2008071664A1 (en) * 2006-12-12 2008-06-19 Smithkline Beecham Corporation Nicotinamide derivative used as a p38 kinase inhibitor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
DK2142514T3 (en) 2007-04-18 2015-03-23 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
AR077642A1 (en) 2009-07-09 2011-09-14 Arena Pharm Inc METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
AU2010294214B2 (en) 2009-09-11 2015-05-07 Vivoryon Therapeutics N.V. Heterocylcic derivatives as inhibitors of glutaminyl cyclase
EP2308847B1 (en) 2009-10-09 2014-04-02 EMC microcollections GmbH Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
EP2549875B1 (en) 2010-03-25 2015-05-13 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN102918027A (en) 2010-04-06 2013-02-06 艾尼纳制药公司 Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2011149921A1 (en) 2010-05-27 2011-12-01 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
PT2648516T (en) * 2010-12-06 2018-11-29 Aclaris Therapeutics Inc Substituted pyridinone-pyridinyl compounds
CN102532037B (en) * 2010-12-16 2015-05-20 上海医药工业研究院 Novel pyrimidine derivatives as well as preparation method and applications thereof
JP6050264B2 (en) 2011-03-16 2016-12-21 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN102321014A (en) * 2011-05-27 2012-01-18 沈阳亿灵医药科技有限公司 Novel di-phenylpyridine derivative
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013144191A1 (en) * 2012-03-29 2013-10-03 Bayer Intellectual Property Gmbh Substituted 2-amino-3-cyanopyridines as inhibitors of sodium-calcium exchange and use thereof for cardiovascular diseases
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CA2979033A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CN106749190B (en) * 2015-11-23 2019-05-17 苏州云轩医药科技有限公司 With the active aminopyrimidine heterocyclic compound of adenosine receptor antagonist and its application
CN106279042B (en) * 2016-08-18 2018-12-11 新发药业有限公司 The method for preparing 2- methyl -4- amino-5-cyanopyrimidine is reacted using Mannich
WO2018162722A1 (en) 2017-03-09 2018-09-13 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Dpp-4 inhibitors for use in treating bone fractures
CN110996951A (en) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 PPAR gamma agonists for the treatment of progressive supranuclear palsy
PL3461819T3 (en) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitors of glutaminyl cyclase
KR102176621B1 (en) * 2018-08-21 2020-11-10 가천대학교 산학협력단 A phenylpyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating Glucagon Receptor activity related diseases containing the same as an active ingredient
EP3910015A4 (en) 2019-12-04 2022-05-04 LG Chem, Ltd. Polycarbonate composition and optical product formed therefrom
CN115850243A (en) * 2022-12-23 2023-03-28 上海天马微电子有限公司 Thermal activation delayed fluorescent material and device

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000020I1 (en) * 1996-04-25 2010-07-08 Prosidion Ltd Method for lowering the blood glucose level in mammals
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
AU766219B2 (en) 1998-02-02 2003-10-09 1149336 Ontario Inc. Method of regulating glucose metabolism, and reagents related thereto
DE19834591A1 (en) 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Use of substances that decrease the activity of dipeptidyl peptidase IV to increase blood sugar levels, e.g. for treating hypoglycemia
CO5150173A1 (en) 1998-12-10 2002-04-29 Novartis Ag COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION
US6583148B1 (en) * 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
US6110949A (en) * 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
GB9928330D0 (en) 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
EP1254113A1 (en) 2000-01-24 2002-11-06 Novo Nordisk A/S N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
MY141144A (en) * 2000-03-02 2010-03-15 Smithkline Beecham Corp 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
TW583185B (en) 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
JP4272338B2 (en) * 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト Pyridine derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues

Also Published As

Publication number Publication date
CN1324015C (en) 2007-07-04
RU2004127576A (en) 2005-09-10
AU2003206833B2 (en) 2006-07-20
GT200300037A (en) 2003-09-12
EP1476435A1 (en) 2004-11-17
WO2003068757A1 (en) 2003-08-21
RU2293731C2 (en) 2007-02-20
US20030216382A1 (en) 2003-11-20
PL371678A1 (en) 2005-06-27
ATE472536T1 (en) 2010-07-15
KR100608414B1 (en) 2006-08-02
MXPA04007744A (en) 2004-10-15
ES2345096T3 (en) 2010-09-15
EP1476435B1 (en) 2010-06-30
US6867205B2 (en) 2005-03-15
TW200303199A (en) 2003-09-01
UY27665A1 (en) 2003-08-29
AU2003206833A1 (en) 2003-09-04
PE20030940A1 (en) 2003-11-19
CA2474578C (en) 2009-08-25
US20050143405A1 (en) 2005-06-30
BR0307665A (en) 2005-01-04
US7022718B2 (en) 2006-04-04
AR038484A1 (en) 2005-01-19
PA8566101A1 (en) 2003-12-19
CN1630644A (en) 2005-06-22
DE60333166D1 (en) 2010-08-12
KR20040089619A (en) 2004-10-21
CA2474578A1 (en) 2003-08-21
JP2005526035A (en) 2005-09-02
JP4359146B2 (en) 2009-11-04

Similar Documents

Publication Publication Date Title
EP1476435B1 (en) Novel pyridin- and pyrimidin-derivatives
AU2003206834B2 (en) Novel pyridine- and quinoline-derivatives
JP7191826B2 (en) tricyclic RHO kinase inhibitor
TWI617308B (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US20060040968A1 (en) 2-(Amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
JP2013545744A (en) Lactam derivatives useful as orexin receptor antagonists
JP4570362B2 (en) Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo [1,2-a] pyrimidine-5 (1H) ON derivatives
EP0802187B1 (en) Hydroxypyridine derivatives, their production and their pharmaceutical use
TW201041876A (en) Carboxamide compounds and their use as calpain inhibitors
JP2000509028A (en) Aminoisoquinoline and aminothienopyridine derivatives and their use as anti-inflammatory agents
JP4725963B2 (en) Arylindenopyridines and arylindenopyrimidines and their use as adenosine A2a receptor antagonists
US6369110B1 (en) Substituted guanidine derivatives and process for producing the same
US5919937A (en) Process for phosphodiesterase IV inhibitors
CA2161436A1 (en) Antiproliferative naphthyridines
KR100991397B1 (en) 4-substituted 2-amino-5-methylimidazole derivatives or pharmaceutically acceptable salt thereof, preparation method thereof and a pharmaceutical composition for the prevention and treatment of ischemic heart diseases containing the same as an active ingredient
GB2330832A (en) Precursors for phosphodiesterase 1v inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2474578

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003704536

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/007744

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003206833

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20038037742

Country of ref document: CN

Ref document number: 1020047012449

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003567888

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004127576

Country of ref document: RU

COP Corrected version of pamphlet

Free format text: FIRST PAGE OF DESCRIPTION DELETED

WWP Wipo information: published in national office

Ref document number: 2003704536

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003206833

Country of ref document: AU